Document:

EX-10.16

 Exhibit 10.16 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Commercial and
Development Collaboration Agreement 
 by and between 

Agendia, Inc. and PAIGE.AI, Inc. 

dated as of November 5, 2020 

 TABLE OF CONTENTS 

 

							
	 	    	 	  	Page	 
			
	1.	    	Definitions	  	 	1	 
			
	2.	    	Licenses	  	 	10	 
			
	 	    	2.1   Paige License Grant	  	10	 
	 	    	2.2   Agendia License Grant	  	11	 
	 	    	2.3   Mutual Data License Grant	  	12	 
	 	    	2.4   No Right to Disclose	  	12	 
	 	    	2.5   Distribution	  	12	 
	 	    	2.6   Effect of Bankruptcy	  	13	 
	 	    	2.7   [***]	  	14	 
	 	    	2.8   No Implied Licenses	  	14	 
			
	3.	    	 Governance
	  	 	14	 
			
	 	    	3.1   Structure	  	14	 
	 	    	3.2   Functions	  	14	 
	 	    	3.3   Meetings	  	15	 
	 	    	3.4   Chairperson	  	15	 
	 	    	3.5   Alliance Managers	  	16	 
	 	    	3.6   Decision-Making	  	16	 
	 	    	3.7   Limitations on JSC Authority	  	17	 
			
	4.	    	 Commercialization
	  	 	17	 
			
	 	    	4.1   Rights and Obligations of Agendia	  	17	 
	 	    	4.2   Rights and Obligations of Paige	  	18	 
	 	    	4.3   Rights and Obligations of Both Parties	  	18	 
	 	    	4.4   Commercialization Plan	  	19	 
	 	    	4.5   Diligence	  	21	 
	 	    	4.6   Reporting	  	21	 
	 	    	4.7   Extra-Territorial Activities	  	21	 
			
	5.	    	 Continuity of Service
	  	 	22	 
			
	 	    	5.1   Support or Supply of CMPBP	  	22	 
	 	    	5.2   [***]	  	22	 
	 	    	5.3   [***]	  	22	 
	 	    	5.4   [***]	  	23	 
	 	    	5.5   [***]	  	23	 
			
	6.	    	 Payments
	  	 	23	 
			
	 	    	6.1   Revenue Sharing	  	23	 
	 	    	6.2   Milestone Payments	  	24	 
	 	    	6.3   Research and Non-Commercial Use	  	24	 
	 	    	6.4   [***]	  	24	 
	 	    	6.5   Payment; Reports	  	24	 

  
 i 

							
	 	    	6.6   Late Payments	  	25	 
	 	    	6.7   Taxes	  	25	 
	 	    	6.8   Records and Audit	  	26	 
			
	7.	    	Intellectual Property Rights	  	 	27	 
			
	 	    	7.1   Background Technology	  	27	 
	 	    	7.2   Collaboration Data and Technology	  	28	 
	 	    	7.3   Patent Filings	  	29	 
	 	    	7.4   Enforcement of Licensed and Collaboration Technology	  	30	 
	 	    	7.5   Defense of Third Party Intellectual Property Claims	  	32	 
	 	    	7.6   Product Marks	  	32	 
			
	8.	    	Confidentiality; Publicity and Publications	  	 	32	 
			
	 	    	8.1   Confidentiality Obligations	  	32	 
	 	    	8.2   Exceptions	  	33	 
	 	    	8.3   Equitable Relief	  	33	 
	 	    	8.4   Press Release; Public Announcements	  	34	 
	 	    	8.5   Publications	  	34	 
			
	9.	    	[Reserved]	  	 	34	 
			
	10.	    	Representations and Warranties; Covenants	  	 	34	 
			
	 	    	10.1  Mutual Representations, Warranties and Covenants	  	34	 
	 	    	10.2  Additional Representations and Warranties of Paige	  	35	 
	 	    	10.3  Additional Representations and Warranties of Agendia	  	37	 
	 	    	10.4  Covenants of Each Party	  	38	 
	 	    	10.5  Compliance with Laws	  	40	 
	 	    	10.6  Disclaimer	  	40	 
			
	11.	    	Indemnification	  	 	40	 
			
	 	    	11.1  Indemnification by Agendia	  	40	 
	 	    	11.2  Indemnification by Paige	  	41	 
	 	    	11.3  Indemnification Procedure	  	41	 
	 	    	11.4  Insurance	  	42	 
	 	    	11.5  Limitation of Liability	  	42	 
			
	12.	    	Term and Termination	  	 	43	 
			
	 	    	12.1  Term	  	43	 
	 	    	12.2  Termination for Material Breach	  	43	 
	 	    	12.3  Termination for Insolvency	  	44	 
	 	    	12.4  Termination for Change of Control	  	44	 
	 	    	12.5  Agendia’s Right to Terminate for Convenience	  	44	 
	 	    	12.6  Agendia’s Right to Terminate for Failure to Supply	  	44	 
	 	    	12.7  Paige’s Right to Terminate for Convenience	  	44	 
	 	    	12.8  Effect of Termination	  	44	 
	 	    	12.9  Survival	  	47	 

  
 ii 

							
	13.	    	Dispute Resolution	  	 	47	 
			
	 	    	13.1  Objective	  	47	 
	 	    	13.2  Escalation to Executives	  	47	 
	 	    	13.3  Arbitration	  	47	 
	 	    	13.4  Equitable Remedies; Court Proceedings	  	48	 
	 	    	13.5  Excluded Matters	  	48	 
	 	    	13.6  Continued Performance	  	48	 
	 	    	13.7  Attorneys’ Fees	  	49	 
			
	14.	    	Force Majeure	  	 	49	 
			
	15.	    	Assignment	  	 	49	 
			
	16.	    	Miscellaneous	  	 	50	 
			
	 	    	16.1  Further Assurances	  	50	 
	 	    	16.2  Relationship of the Parties	  	50	 
	 	    	16.3  Notices	  	50	 
	 	    	16.4  Interpretation	  	51	 
	 	    	16.5  Headings	  	51	 
	 	    	16.6  Entire Agreement	  	51	 
	 	    	16.7  Expenses	  	51	 
	 	    	16.8  No Third-Party Beneficiaries	  	51	 
	 	    	16.9  Amendment; Modification; Waiver	  	52	 
	 	    	16.10  Cumulative Remedies	  	52	 
	 	    	16.11  Severability	  	52	 
	 	    	16.12  Governing Law; Submission to Jurisdiction	  	52	 
	 	    	16.13  Waiver of Jury Trial	  	52	 
	 	    	16.14  Counterparts	  	53	 

  
 iii 

 Commercial and Development Collaboration Agreement 

This Commercial and Development Collaboration Agreement (“Agreement”), dated and effective as of November 5, 2020 (the
“Effective Date”), is by and between Agendia, Inc., a Delaware corporation, having its principal place of business at 22 Morgan, Irvine, California 92618 (“Agendia”) and PAIGE.AI, Inc., a Delaware corporation,
having its principal place of business at 11 Times Square, Floor 37, New York, New York 10036 (“Paige”) (collectively, the “Parties,” or each, individually, a “Party”). 

RECITALS 
 WHEREAS,
Agendia is a precision oncology company that develops and markets genomic diagnostic products, including, without limitation, software, data, algorithms, models, technology and other information that support its in vitro diagnostic test products
that (i) use microarrays and target enrichment next-generation sequencing (NGS) and technology platforms to create and analyze gene expression profiles from breast cancer tissue samples, and (ii) produce results based on its proprietary
analysis (collectively, the “Agendia Platform”); Agendia’s diagnostic products using the foregoing include the MammaPrint (“MammaPrint” or “MP”) and BluePrint (“BluePrint” or
“BP”) tests; 
 WHEREAS, Paige has developed an AI-native digital pathology
ecosystem, including, without limitation, software, data, algorithms, models, technology and other information, that supports the pathologist, accelerates new biomarker discovery, and is built for new insight generation (“Paige
Offering”); 
 WHEREAS, the Parties entered into a certain R&D Collaboration Agreement dated as of December 9, 2019
(“Existing Agreement”) wherein the Parties agreed to separately negotiate an agreement for the commercialization of any results of their collaboration stemming from the Existing Agreement; 

WHEREAS, this Agreement outlines that further commercialization and the terms and conditions for that further collaboration between the
Parties; and 
 WHEREAS, after extensive discussion, Paige and Agendia desire to collaborate and use the Paige Platform (as defined
herein) and Paige’s computational pathology and machine learning technology to develop and commercialize a digital emulation of MammaPrint (“Collaboration MammaPrint”, or “CMP”) and BluePrint
(“Collaboration BP” or “CBP”) (collectively or individually, “Collaboration MammaPrint-BluePrint” or “CMPBP”) in the Territory on the terms and conditions and as further defined
herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and terms and conditions set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1.
Definitions. For purposes of this Agreement, the following terms have the following meanings: 
 1.1 “Acquirer” has
the meaning set forth in Section 15.1(b). 

  
 1 

 1.2 “Action” has the meaning set forth in Section 7.4(b). 

1.3 “Affiliate” of a Person means any other Person that, at any time during the Term, directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with, such Person. For purposes of this definition only, the term “control” means, and “controlled by” and “under common control
with” have correlative meanings and means possession, directly or indirectly of greater than fifty percent (50%) of the voting equity of another entity (or other comparable interest for an entity other than a corporation), or the power to
direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. 

1.4 “Agendia” has the meaning set forth in the preamble. 

1.5 “Agendia Indemnified Party” has the meaning set forth in Section 11.2. 

1.6 “Agendia Licensed Know-How” means all
Know-How Controlled by Agendia or its Affiliates as of the Effective Date or at any time during the Term, including Agendia’s interest in all Know-How within the
Collaboration Technology, in each case that is necessary for the Development or Commercialization of CMPBP in the Field in the Territory. 

1.7 “Agendia Licensed Patent Rights” means (a) the patents and patent
applications listed on Schedule 1.7; and (b) all Patent Rights in the Territory Controlled by Agendia or its Affiliates as of the Effective Date or at any time during the Term that Cover Agendia Licensed
Know-How. 
 1.8 “Agendia Licensed Technology” means
the Agendia Licensed Know-How and the Agendia Licensed Patent Rights, including the Agendia Platform. 

1.9 “Agendia Platform” has the meaning set forth in the preamble; it is a grouping of Intellectual Property Rights of Agendia
that are used as a base upon which other applications, procedures or technologies are developed. 
 1.10 “Aggregate
Payment” means the aggregate consideration received by Paige to date pursuant to the terms and conditions of this Agreement. [***]. Any payments to Paige related to the achievement of Milestone Events shall be excluded from the
calculation of the Aggregate Payment. 
 1.11 “Agreement” has the meaning set forth in the preamble. 

1.12 “Alliance Manager” has the meaning set forth in Section 3.5. 

1.13 “Annual Period” means the twelve (12) month period beginning on the first day of the calendar quarter following the
Effective Date, and each successive twelve (12) month period thereafter. 
 1.14 “Auditor” has the meaning set forth
in Section 6.8(d). 

  
 2 

 1.15 “Background Intellectual Property
Rights” means any and all Intellectual Property Rights that are owned or controlled by a Party as of the Effective Date of this Agreement or are acquired or developed by a Party thereafter outside the performance of this Agreement.
For the avoidance of doubt, Paige Background Intellectual Property Rights includes the Paige Offering. 
 1.16 “Business
Day” means a day other than a Saturday, Sunday, or other day on which commercial banks in New York, New York are authorized or required by Law to be closed for business. 

1.17 “Change of Control” means, with respect to a Party: (a) an acquisition, reorganization, merger, or consolidation of
such Party by or with a Third Party in which the holders of the voting securities of such Party outstanding immediately before such transaction cease to beneficially own at least fifty percent (50%) of the combined voting power of the surviving
entity, directly or indirectly, immediately after such transaction; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates (if applicable), becomes the beneficial owner of fifty percent (50%) or
more of the combined voting power of the outstanding securities of such Party; or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s assets. 

1.18 “CMPBP” means Collaboration MammaPrint-BluePrint, which, collectively or individually, is a digital emulation of
MammaPrint (“Collaboration MP” or “CMP”) and/or BluePrint (“Collaboration BP” or “CBP”) Developed using the Licensed Technology and any Improvements Developed that are
directly related to CMPBP which the Parties have designated for Commercialization in a Commercialization Plan in accordance with Section 4.4, which, in each case, is Covered by Licensed Technology. 

1.19 “Collaboration” means the alliance of Paige and Agendia established for the purpose of Development and Commercialization
of CMPBP pursuant to this Agreement. 
 1.20 “Collaboration BP” or “CBP” means Collaboration BluePrint
which is to be Developed pursuant to the terms and conditions of this Agreement. 
 1.21 “Collaboration MP” or
“CMP” means Collaboration MammaPrint which is to be Developed pursuant to the terms and conditions of this Agreement. 

1.22 “Collaboration Patents” has the meaning set forth in Section 8.2(b). 

1.23 “Collaboration Technology” means all inventions (whether or not patentable), works of authorship (whether
or not copyrightable), and Know-How invented, created, conceived, developed, or otherwise made by a Party’s employees, agents, or independent contractors, either alone or jointly with the other
Party’s employees, agents, or independent contractors, directly and solely related to CMPBP, during the course of the Collaboration or during the term of the Existing Agreement. Collaboration Technology shall not include Trademarks. 

1.24 “Commercial Product Readiness” means such time when CMPBP has satisfied any applicable commercial and operational
standards related to processing, validation, quality control and quality assurance/management testing and is ready for Commercialization but has yet to obtain any required approval or clearance of the relevant Governmental Authority. 

  
 3 

 1.25 “Commercialization” means, in respect of CMPBP, the conduct of any and
all activities directed to the marketing, distribution, offer for commercial sale, and commercial sale and support of CMPBP, but excluding regulatory matters, and Development activities. “Commercialize” means to engage in
Commercialization. 
 1.26 “Commercialization Plan” has the meaning set forth in Section 4.4. 

1.27 “Commercially Reasonable Efforts” means, with respect to a Party and its objectives or obligations concerning CMPBP
under this Agreement, such efforts and resources consistent with those commonly used by a company in the clinical diagnostics industry to achieve a similar objective or fulfill a similar obligation concerning a product of similar market potential at
a similar stage in product life as such CMPBP, taking into account the patent or other proprietary position, competitive market conditions, profitability and financial return (including Third Party costs and expenses, any payment due to a Party
under this Agreement), and all other relevant legal, scientific, technical, and commercial factors. 
 1.28 “Competing
Product” means any product, method, process, or other subject matter that is, or readily can be, applied, used, or adapted for any use or application in the Field in substitution for or competition with CMPBP. 

1.29 “Concordance” means accuracy which is defined as the sum of the diagonal of a confusion matrix divided by the total
number of cases in a test set drawn uniformly at random to approximately match the distribution of samples Agendia has received from patients for MammaPrint or BluePrint, as applicable, in a blind validation. 

1.30 “Confidential Information” means all non-public, confidential, or
proprietary information and materials of a Party or its Affiliates, whether in oral, written, electronic, or other form or media, whether or not such information and materials are marked, designated, or otherwise identified as
“confidential” and includes any information and materials that, due to the nature of the subject matter or circumstances surrounding the disclosure thereof, would reasonably be understood to be confidential or proprietary. Without limiting
the foregoing, Confidential Information includes (a) the terms and existence of this Agreement, including correspondence, communications, and notices provided hereunder; (b) the terms and existence of the Existing Agreement, including
correspondence, communications and notices provided thereunder; and (c) all information contained in or disclosed in connection with any Commercialization Plan delivered under Section 4 or report delivered under Section 4.6. 

Confidential Information does not include information or materials that the receiving Party can demonstrate by documentation: (w) was already known to
the receiving Party or its Affiliates without restriction on use or disclosure prior to the disclosure of such information directly or indirectly by or on behalf of the disclosing Party; (x) was or is independently developed by the receiving
Party or its Affiliates without reference to or use of any Confidential Information of the disclosing Party; (y) was or becomes generally known by the public other than by breach of this Agreement by, or other wrongful act of, the receiving
Party or its Affiliates; or (z) was disclosed to the receiving Party or its Affiliates by a Third Party who was not, at the time of disclosure, under any obligation to the disclosing Party or any other Person to maintain the confidentiality of
such information. 

  
 4 

 1.31 “Continuity of Service Period” has the
meaning set forth in Section 5.2. 
 1.32 “Control” means, with respect to any Intellectual Property Rights, the
possession by a Party, whether by ownership or license (other than a license granted to such Party under this Agreement), of the right to grant access to or a license (or sublicense) under such Intellectual Property Rights on the terms and
conditions set forth in this Agreement without requiring the consent of any Third Party or violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required under this Agreement to grant
the other Party such access or license. 
 1.33 “Cover” means, as to a particular subject matter at issue and a Valid Claim
of a relevant Patent Right, that, in the absence of a license granted under, or ownership of, such Patent Right, the making, using, selling, offering for sale, or importation of such subject matter would infringe such Valid Claim. 

1.34 “Cure Period” has the meaning set forth in Section 12.2. 

1.35 “Customer Data” has the meaning set forth in Section 2.3(c) and includes Patient Data. 

1.36 “Development” means, for a particular product, all activities involved in producing, processing, coding, validating,
researching, quality control, quality assurance/management, testing (technical, preclinical, clinical and otherwise, as applicable), obtaining regulatory approval/clearance and release of such product, and any component thereof.
“Develop” or “Developing” means to engage in Development. 
 1.37 “Development
Data” means any data used to Develop or generated during the Development of CMPBP, during the term of the Existing Agreement or this Agreement. 

1.38 “Development Know-How” means all Licensed Know-How that is reasonably necessary or useful to Develop CMPBP in the Field. 
 1.39
“Digital Media” means a Uniform Resource Locator (URL), Internet domain name, or similar electronic address, an Internet site, a Facebook page, Twitter account, Pinterest account, or any other social media, or other
online means of advertising, marketing, offering for sale, or selling products or services, in each case, whether such media or other means are now known or developed in the future. 

1.40 “Dispute” has the meaning set forth in Section 13.1. 

1.41 “Dispute Notice” has the meaning set forth in Section 13.1. 

1.42 “Distributor” shall mean one or more Person(s) party to an agreement with Agendia for the distribution, marketing and
sale of certain products, including CMPBP. 

  
 5 

 1.43 “Documentation” shall mean system specifications, hardware
requirements, technical manuals, and all other user instructions regarding the capabilities, operation, installation and use of the Software. 

1.44 “Effective Date” has the meaning set forth in the preamble. 

1.45 “Error” means a failure of the Software to operate in material conformance with Specifications. 

1.46 “Executives” has the meaning set forth in Section 13.2. 

1.47 “Field” means the field of breast cancer. 

1.48 “First Commercial Sale” means, with respect to CMPBP, the first arm’s length sale, lease or license of, or other
disposition of rights in, CMPBP in the Territory to a Third Party, other than a sale or other disposal of CMPBP for test marketing, sampling and promotional uses, development, charitable purposes, or similar use. 

1.49 “Force Majeure Event” has the meaning set forth in Section 14. 

1.50 “Governmental Authority” means any federal, state, or local government, or political subdivision thereof,
or any agency or instrumentality of the government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent the
rules, regulations, or orders of such organization or authority have the force of Law), or any arbitrator, court, or tribunal of competent jurisdiction. 

1.51 “Improvement” means any Collaboration Technology that is an enhancement, improvement, variation, or modification
directly related to CMPBP. 
 1.52 “In-License Agreement” means any
agreement in effect as of the Effective Date under which any Third Party grants a license to a Party under any Intellectual Property Rights necessary for the Development or Commercialization of CMPBP in the Territory. 

1.53 “In-Licensor” means any Third Party granting a license to a Party under any In-License Agreement. 
 1.54 “Indemnified Claim” has the meaning set forth
in Section 11.1. 
 1.55 “Indemnified Party” means a Paige Indemnified Party or an Agendia Indemnified Party. 

1.56 “Indemnifying Party” has the meaning set forth in Section 11.3. 

1.57 “Intellectual Property Rights” means all rights in Know-How, Patent Rights,
Trademarks, copyrights, database rights, domain names, topography rights, and design rights and all goodwill associated therewith and symbolized thereby, whether registered or unregistered, including all applications and rights to apply for
registration inventions, discoveries, concepts, improvements, Know-How, trade secrets and secrecy rights, as well as all similar or equivalent rights or forms of protection which may exist anywhere in the
world. 

  
 6 

 1.58 “Joint Steering Committee” (or
“JSC”) has the meaning set forth in Section 3.1. 
 1.59
“Know-How” means all confidential or proprietary technical information, 
 know-how, data, inventions, improvements, discoveries, trade secrets and secrecy rights, processes, procedures, techniques, developments, compositions, products, compounds, material, methods, algorithms, formulas,
formulations, protocols, result of experimentation or testing, technology, ideas, concepts or other proprietary information and documentation thereof (including related papers, invention disclosures, laboratory notebooks, drawings, flowcharts,
diagrams, and specifications), in each case whether or not copyrightable or patentable, and whether in written, electronic, oral, or any other tangible or intangible form or medium. 

1.60 “Law” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment,
decree, other requirement, or rule of law of any Governmental Authority, including all applicable security, privacy, and enforcement laws, regulations, and standards, including but not limited the Health Insurance Portability and Accountability Act
of 1996 and the rules and regulations promulgated thereunder, as the same may be amended from time to time (collectively, “HIPAA”). 

1.61 “Licensed Know-How” means Agendia Licensed
Know-How and Paige Licensed Know-How. 
 1.62
“Licensed Patent Right” means Agendia Licensed Patent Right and Paige Licensed Patent Right. 

1.63 “Licensed Technology” means Agendia Licensed Technology and Paige Licensed Technology. 

1.64 “Losses” means all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest,
awards, penalties, fines, costs, or expenses of whatever kind, including professional fees and reasonable attorneys’ fees. 
 1.65
“Materials” means any tangible chemical, biological, or physical materials and any software and related documentation. 

1.66 “Milestone Event” has the meaning set forth in Section 6.2. 

1.67 “Milestone Payment” has the meaning set forth in Section 6.2. 

1.68 “Paige” has the meaning set forth in the preamble. 

1.69 “Paige Breast Biomarkers” has the meaning set forth in Section 10.4(c)(iii). 

1.70 “Paige Indemnified Party” has the meaning set forth in Section 11.1. 

  
 7 

 1.71 “Paige Licensed Know-How”
means all Know-How Controlled by Paige or its Affiliates as of the Effective Date or at any time during the Term, including Paige’s interest in all Know-How within
the Collaboration Technology, in each case that is necessary for the Development or Commercialization of CMPBP in the Field in the Territory. 

1.72 “Paige Licensed Patent Rights” means (a) the patents and patent
applications listed on Schedule 1.72 and (b) all Patent Rights in the Territory Controlled by Paige or its Affiliates as of the Effective Date or at any time during the Term that Cover Paige Licensed
Know-How. 
 1.73 “Paige Licensed Technology” means the Paige Licensed Know-How and Paige Licensed Patent Rights, including the Paige Platform. 
 1.74 “Paige
Marks” means Trademarks, including corporate names and corporate logos, of Paige set forth on Schedule 1.74 and such other Trademarks as Paige may designate in writing from time to time. 

1.75 “Paige Offering” has the meaning set forth in the preamble; it is a grouping of Intellectual Property
Rights of Paige that are used as a base upon which other applications, processes or technologies are developed, including the Paige Platform. 

1.76 “Paige Platform” means the collection of the vendor-neutral viewer (“Paige FullFocus”),
the cloud-based data storage, compute and inference services and the appliance to transfer Patient Data into FullFocus (“Paige Data Bridge”). 

1.77 “Party” has the meaning set forth in the preamble. 

1.78 “Patent Rights” means all rights and interests in issued patents and patent applications (whether provisional or non-provisional), including continuations, continuations-in- part, divisionals, substitutions, reissues, reexaminations, or restorations of any of the foregoing, and other
Governmental Authority-issued indicia of invention ownership (including certificates of invention, petty patents, and utility models). 

1.79 “Patient Data” means whole slide images of patient tissue and, to the extent the relevant Party has the
legal authority to transmit such information, the associated metadata and patient information necessary to provide the CMPBP. For clarity, the Parties agree and acknowledge that neither shall allow the use of associated metadata and patient
information without the appropriate consents. 
 1.80 “Person” means an individual, corporation, partnership, joint
venture, limited liability company, Governmental Authority, unincorporated organization, trust, association, or other entity. 
 1.81
“Product Mark” has the meaning set forth in Section 7.6(a). 
 1.82 “Quarterly
Period” means the three (3) month period beginning on the first day of the calendar quarter following the Effective Date, and each successive three (3) month period thereafter. 

  
 8 

 1.83 “Representative” means a Party’s employees, officers, directors,
consultants, and legal, technical, and business advisors. 
 1.84 “Revenue Sharing” has the meaning set forth
in Section 6.1. 
 1.85 “Rules” has the meaning set forth in Section 13.3. 

1.86 “Software” means [***]. 

1.87 “Specifications” means the specifications, technical, business and functional requirements, standards and descriptions
including the applicable format and content parameters and published Documentation, if any, to which the Software are to comply. 
 1.88
[***] 
 1.89 [***] 
 1.90
“Sublicensee” means one or more Person(s) party to a sublicense agreement with Agendia (or any its Affiliates) for the development of a digital pathology portal during a Continuity of Service Period [***] 

1.91 “Term” has the meaning set forth in Section 12.1(a). 

1.92 “Territory” means [***] 

1.93 “Third Party” means a Person other than a Party or a Party’s Affiliate. 

1.94 “Third Party IP Claim” has the meaning set forth in Section 7.5. 

1.95 “Total Payments Received” means, with respect to any CMPBP, the aggregate of received payments or consideration received
for sales or other dispositions of CMPBP directly by Paige or by Agendia from Third Parties, including any Distributor of Agendia. 
 1.96
“Trademarks” means all trademarks, service marks, brands, logos, trade dress, trade names, and other indicia of source or origin. 

1.97 “Update” means and includes the modifications, Error corrections, bug fixes, workarounds or revisions made to the
Software provided by Paige: (i) to improve upon or repair existing features and operations within the Software, (ii) to ensure compatibility with new releases of existing systems (including hardware, operating systems and middleware) and
external services through standardized interfaces, or (iii) to comply with applicable laws, regulations, industry standards or market practice. 

  
 9 

 1.98 “U.S. FDA” means the Food and Drug Administration of the
U.S. Department of Health and Human Services or any successor agency thereto. 
 1.99 “Valid Claim” means: (a) a claim
of an issued and unexpired Patent Right that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, and that has not been abandoned, disclaimed,
denied, or admitted to be invalid or unenforceable through reissue, re-examination, inter partes review, post-grant review, or disclaimer or otherwise; or (b) a claim of a pending patent application that
has not been cancelled, withdrawn, or abandoned or finally rejected by an administrative agency action that is not appealable or has not been appealed within the time allowed for appeal. 

2. Licenses. 
 2.1
Paige License Grant. Subject to the terms and conditions of this Agreement, Paige hereby grants to Agendia, during the Term, a limited, non-exclusive (except as otherwise set
forth below), non-transferable (except as set forth in Section 15), revocable license in the Territory to use the following data and materials provided by Paige to Agendia solely for the limited purposes
of conducting the Collaboration as specifically described herein: 
 (a) Algorithm validation results of CMPBP; 

(b) Access to the Paige Platform to upload sample images and Patient Data, and view the slide and the image analysis resulting
from the application of CMPBP; 
 (c) Marketing and instructional materials related to the Paige Platform, e.g., demos,
screenshots, etc., necessary to support CMPBP; 
 (d) Access to and integration between the Agendia Platform and the Paige
Platform to facilitate product orders, sample analysis, report generation and delivery, clinical support and technical support; 

(e) An exclusive license in the Field and in the Territory during the Term, with the right to enter into distribution
agreements solely as provided in Section 2.5, under the Paige Licensed Technology (other than Development Know- How) only to Commercialize (but not to Develop or have Developed) CMPBP; 

(f) An exclusive license in the Field and in the Territory during the Term under the Development
Know-How to Develop or have Developed CMPBP solely for Commercialization of such CMPBP; 

(g) A non-exclusive license in the Field and in the Territory during the Term, with the
right to enter into distribution agreements solely as provided in Section 2.5, to use the Paige Marks solely in connection with the Commercialization of CMPBP in accordance with Paige’s most current branding guidelines. Agendia shall
provide Paige with fifteen (15) days to review and approve of all materials using the Paige Marks; and 

  
 10 

 (h) During a Continuity of Service Period under this Agreement pursuant to
Section 5.2 herein, an exclusive, irrevocable license to continue to exercise the licenses and rights provided to Agendia in this Section 2.1, with a right to: 

(i) enter into distribution agreements solely as provided in Section 2.5; and 

(ii) grant sublicenses to Sublicensees, pursuant to this Section 2.1. 

2.2 Agendia License Grant. Subject to the terms and condition of this Agreement, Agendia (or its parent
entity, Agendia, N.V., as applicable) hereby grants to Paige, during the Term, a limited, non-exclusive (except as set forth below), non-transferable (except as set
forth in Section 15) revocable license in the Territory to use the following data and materials provided by Agendia to Paige solely for the limited purposes of conducting the Collaboration as specifically described herein: 

(a) Certain images of pathology slides and related data provided by Agendia to Paige, at Agendia’s sole discretion, for
Development of CMPBP; 
 (b) Reasonable marketing and service materials for the purposes of marketing CMPBP; 

(c) Access to and integration between the Paige Platform and the Agendia Platform to facilitate CMPBP orders, sample analysis,
report generation and delivery; 
 (d) An exclusive license in the Field and in the Territory during the Term, without the
right to grant sublicenses, under the Agendia Licensed Technology (other than Development Know-How) to Commercialize (but not to Develop or have Developed) CMPBP; 

(e) An exclusive license in the Field and in the Territory during the Term, without the right to grant sublicenses, under the
Development Know-How to Develop or have Developed CMPBP solely for Commercialization of such CMPBP; and 

(f) A non-exclusive license in the Field and in the Territory during the Term, with no
right to grant sublicenses, to use the Product Marks solely in connection with the Commercialization of CMPBP. 

  
 11 

 2.3 Mutual Data License Grant. Each Party hereby grants the other Party, during the
Term of this Agreement, and during any Continuity of Service Period, with a limited, non-exclusive (except as set forth in Sections 2.1 and 2.2), non-transferable
(except as set forth in Section 15) revocable license in the Territory in the Field solely to use and make use of: 

(a) its respective Background Intellectual Property Rights, excluding all Paige source code, object code and algorithms,
required for and limited to the Development and Commercialization of CMPBP and solely for purposes of carrying out its rights and obligations under this Agreement and to perform its required activities therein; 

(b) Development Data solely for the purposes of customer support, quality and regulatory requirements, and overall product
improvements related solely to CMPBP; and 
 (c) any customer uploaded data [***] 

For clarity, with respect to Paige, Paige shall not be permitted to use any aspect of the Development Data or the Customer Data generated by CMPBP in
connection with the Development, training or validation of other Paige products, without the prior written consent of Agendia. Notwithstanding the foregoing, Paige shall have limited right to use the Development Data and the Customer Data for the
sole purpose of updating or fixing the Paige Platform (which excludes any Paige algorithms) to address any issues directly related to servicing and/or delivering CMPBP. For the avoidance of doubt, any updates or fixes made to the Paige Platform
using the Development Data and the Customer Data shall not be considered Collaboration Technology and shall be wholly owned by Paige and incorporated into the Paige Platform. 

2.4 No Right to Disclose. Notwithstanding the grant of licenses under Article 2 of this
Agreement, and except as otherwise provided in Sections 2.6 and 5, neither Party shall be obligated to disclose to the other Party any of its Background Intellectual Property Rights (including its algorithms). 

2.5 Distribution. 

(a) Permitted Distributors. Agendia shall have the right to enter into distribution agreements with and grant access to CMPBP
under the rights and licenses granted in Sections 2.1(e), 2.1(g) and 2.1(h) to: (i) its Affiliates without the prior consent of Paige; (ii) existing Distributors set forth in Exhibit B, without the prior consent of Paige; (iii) any
additional Distributors to the extent consistent with Agendia’s past practice of distributing its products and the conditions, if any, set forth in the Commercialization Plan, without the prior consent of Paige; and (iv) any other Third
Party with Paige’s prior consent. 

  
 12 

 (b) Distribution Requirements. Agendia represents and warrants that:
(i) all existing and any additional distribution agreements granted by Agendia to Distributors relating to the sales, marketing and distribution of CMPBP under the licenses granted hereunder must be in writing and be subject to and consistent
with the applicable terms and conditions of this Agreement; (ii) Paige shall be provided advance written notice of each such distribution agreement; (iii) Agendia shall be responsible to Paige for the performance of its Distributors and
Affiliates; and (iv) upon request, Agendia shall use Commercially Reasonable Efforts to provide Paige with a copy of any such distribution agreement to assess the compliance of such agreement with the terms and conditions of this Agreement so
long as such act does not violate applicable Law, such agreements may be reasonably redacted to remove information not relevant to such compliance assessment. Without limiting the foregoing, all distribution agreements granted by Agendia must
include provisions for (i) assignment of Intellectual Property Rights consistent with a Party’s obligations under Section 8.2(c); and (ii) protection of Confidential Information (as defined in this Agreement) at least as
stringent as those contained in Section 8. Any distribution agreement granted to a Distributor under this Section 2.5 must prohibit such Distributor from any transfer or assignment of any right of distribution to any other Third Parties
without the prior written consent of Agendia and Paige. 
 2.6 Effect of Bankruptcy. 

(a) Paige Bankruptcy. All rights and licenses granted by Paige under the Paige Licensed Technology are and
will be deemed to be rights and licenses to “intellectual property,” and any Materials to which Agendia is granted access hereunder are and will be deemed to be an “embodiment” of “intellectual property”, in each case,
as such terms are used in and interpreted under section 365(n) of the United States Bankruptcy Code (the “Code”) (11 U.S.C. § 365(n)). Agendia has all rights, elections, and protections under the Code and all other applicable
bankruptcy, insolvency, and similar Laws with respect to this Agreement and the subject matter hereof. Without limiting the generality of the foregoing, Paige acknowledges and agrees that, if Paige or its estate becomes subject to any bankruptcy or
similar proceeding, subject to Agendia’s rights of election under section 365(n), all rights, licenses, and privileges granted to Agendia under the Paige Licensed Technology, [***], will continue subject to the respective terms and conditions
hereof, and will not be affected, even by Paige’s rejection of this Agreement. For clarity, the Paige Licensed Technology does not include the Background Intellectual Property Rights of Paige unrelated to the Collaboration and outside the
performance of this Agreement. 
 (b) Agendia Bankruptcy. All rights and licenses granted by Agendia under the Agendia
Licensed Technology are and will be deemed to be rights and licenses to “intellectual property,” and any Materials to which Paige is granted access hereunder are and will be deemed to be an “embodiment” of “intellectual
property”, in each case, as such terms are used in and interpreted under section 365(n) of the Code. (11 U.S.C. § 365(n)). Paige has all rights, elections, and 

  
 13 

 
protections under the Code and all other applicable bankruptcy, insolvency, and similar Laws with respect to this Agreement and the subject matter hereof. Without limiting the generality of the
foregoing, Agendia acknowledges and agrees that, if Agendia or its estate becomes subject to any bankruptcy or similar proceeding, subject to Paige’s rights of election under section 365(n), all rights, licenses, and privileges granted to Paige
under the Agendia Licensed Technology will continue subject to the respective terms and conditions hereof, including any restrictions on the uses of such technology on Paige pursuant to Section 10.4, and will not be affected, even by
Agendia’s rejection of this Agreement. For clarity, the Agendia Licensed Technology does not include the Background Intellectual Property Rights of Agendia unrelated to the Collaboration and outside the performance of this Agreement. 

2.7 Exclusivity. [***] 

2.8 No Implied Licenses. Except as expressly set forth in this Agreement, neither Party will be deemed by estoppel or implication to
have granted the other Party any license or other right to any Intellectual Property Rights of such Party or its Affiliates. 
 3.
Governance. 
 3.1 Structure. [***], the Parties shall establish a joint steering committee (“Joint Steering
Committee” or “JSC”) to oversee, review, and guide the strategic direction of the Collaboration. Each Party shall appoint two (2) of its executives or managers who have appropriate expertise, experience, and authority
to address Development and Commercialization matters to serve as its representatives on the JSC. The total number of representatives on the JSC may be changed by mutual agreement of the Parties; provided that there will at all times be an equal
number of representatives of each of Paige and Agendia on the JSC. Each Party shall notify the other Party of its initial JSC representatives within fifteen (15) days after the Effective Date. Each Party may change its JSC representatives at
any time by notice to the other Party. 
 3.2 Functions. In furtherance of the Collaboration’s objectives, the JSC will act as a
joint consultative body and, to the extent expressly provided herein, a joint decision-making body. In particular, the JSC will: 

(a) be a forum for discussion and exchange of information and analysis between the Parties concerning Commercialization of
CMPBP in the Territory; 

  
 14 

 (b) review, discuss, and approve the Commercialization Plans (and any
material amendments thereto) and the Parties’ activities with respect to the Commercialization of CMPBP in the Territory; 

(c) review and discuss the major findings of market research with respect to CMPBP in the Territory; 

(d) review and approve Agendia’s brand and product positioning strategy for CMPBP in the Territory; 

(e) review Paige’s plans and performance for the Development and supply of CMPBP to Agendia for Commercialization; 

(f) establish additional joint subcommittees or working groups, each composed of an equal number of representatives from each
Party, to perform certain functions as the JSC deems necessary or advisable to further the purpose of this Agreement, approve decisions of any joint subcommittee, including appointment of members and membership changes, and resolve any disputed
matter submitted to it by such subcommittee; 
 (g) perform such other functions as are appropriate to further the objectives
of the Collaboration as mutually determined by the Parties; and 
 (h) Evaluate any accounting discrepancies related to
Revenue Sharing and adjust, as needed, on a quarterly basis. 
 As part of its preliminary and pending activities, the JSC shall review and
approve the initial statement of work attached hereto as Exhibit A. 
 3.3 Meetings. The JSC will meet as needed but not less
than once each Quarterly Period during the Term. JSC meetings will be held at such times and places or in such form, including in-person, by telephone or video conference, as the JSC determines, except that in-person meetings of the JSC will alternate between the Parties’ offices (or shall occur virtually on-line as the JSC determines). Any JSC member may designate a
substitute of equivalent experience and seniority to attend and perform the functions of that JSC member at any JSC meeting on notice to the other Party [***]before such JSC meeting. Each Party may invite additional Representatives to attend JSC
meetings as observers or to make presentations, in each case without any voting authority, on notice to the other Party [***] before the JSC meeting that the Representative will attend. 

3.4 Chairperson. Agendia shall appoint one of the JSC members to act as the initial JSC chairperson during such period as the JSC shall
designate. At the end of each such designated period during the Term, the Parties shall alternate in appointing the chairperson for the next such period. The JSC chairperson will be responsible for: 

(a) calling and presiding over each JSC meeting during his or her tenure as chairperson; 

  
 15 

 (b) preparing and circulating the agenda for each such meeting; and 

(c) preparing draft minutes of each such meeting and providing a copy of the draft minutes to each JSC member [***]after each
such meeting for approval, which will be deemed to have been given unless any JSC member objects [***]after receipt of the draft minutes. 

3.5 Alliance Managers. Each Party shall appoint a Representative to serve as such Party’s primary liaison (each, an
“Alliance Manager”) with the other Party for all matters relating to the Collaboration and to facilitate communication and collaboration between the Parties. Each Party may replace its Alliance Manager at any time by providing
notice to the other Party. The Alliance Managers will be entitled to attend all JSC meetings and each Alliance Manager may bring any matter to the attention of the JSC if such Alliance Manager reasonably believes that such matter requires the
JSC’s attention. Each Party shall notify the other Party of its initial Alliance Manager [***]after the Effective Date. 
 3.6
Decision-Making. 
 (a) Unanimous Decision. All JSC decisions in any matter requiring the JSC’s action or
approval must be unanimous, with Paige’s representatives on the JSC collectively having one vote and Agendia’s representatives on the JSC collectively having one vote. No JSC vote may be taken unless a minimum of one Representative of each
Party is present at any meeting of the JSC. The JSC shall make all decisions and take other actions in good faith and with due care, after consideration of the information that is reasonably available to it, with the intention that the resulting
decision or action will: 
 (i) not breach or conflict with any requirements or other provisions of this Agreement; and 

(ii) maintain or increase the likelihood that the Parties will achieve the objectives of the Collaboration; provided that, the
JSC is expressly prohibited from taking into account any interests of a Party, or of any members of the JSC, other than their respective interests in achieving the objectives of the Collaboration. 

(b) Disputed Matters; Deciding Vote. If the JSC cannot reach a unanimous decision at a regularly scheduled JSC meeting or
within fifteen (15) Business Days thereafter, the matter will be considered a Dispute under this Agreement and either Party may thereafter initiate the dispute resolution procedure set forth in Section 13; provided, however, that Agendia
will have the deciding vote on any matter related to the pricing of CMPBP, the approval of Distributors and issues related to reimbursement, pursuant to the Commercialization Plan. 

  
 16 

 (c) Exceptions. Notwithstanding Section 3.6(b), neither Party has any
right to exercise a deciding vote (i) in a manner that excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) in a manner that negates any consent rights or other rights specifically allocated to
the other Party under this Agreement; (iii) in a manner that would require the other Party to perform activities that the other Party has not agreed to perform as set forth in this Agreement or the Commercialization Plan or as otherwise agreed
in writing by the other Party; (iv) in a manner that would require a Party to perform any act that it reasonably believes to be inconsistent with any Law, any approval, order, policy, or guidelines of a Governmental Authority, or any of such
Party’s ethical requirements or ethical guidelines; (v) to allocate Intellectual Property Rights; or (vi) to determine that such Party has fulfilled any obligation under this Agreement or that the other Party has breached any obligation
under this Agreement. 
 3.7 Limitations on JSC Authority. The JSC will have only the
powers expressly delegated to it in this Section 3 and elsewhere in this Agreement and will have no authority to (a) amend, modify, or waive compliance with this Agreement; (b) act on behalf of either Party in relation to any Third
Party; or (c) take any action on matters that are expressly reserved to or delegated to a Party. By way of illustration, Agendia shall maintain control of activities as provided in Section 3.6(b). Each Party will retain the rights, powers,
and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties otherwise
expressly agree in writing. 
 4. Commercialization. The Parties shall collaborate to Develop and Commercialize CMPBP to achieve the
target performance criteria as determined by the JSC. The principal rights and obligations of the Parties, with respect to the Collaboration, are set out below: 

4.1 Rights and Obligations of Agendia. In connection with its rights and obligations, under this Agreement, Agendia shall: 

(a) Co-Develop CMPBP with Paige to achieve target product performance and meet
regulatory requirements; 
 (b) Secure and provide sample whole-slide images of breast tissue and their related data to Paige
to enable Development of CMPBP; 
 (c) Conduct and sponsor clinical studies to generate clinical data, evidence and
publications/publicity to support regulatory clearance, inclusion in guidelines, and commercial adoption of CMPBP (subject to review by the JSC, whose consent will not be unreasonably withheld, delayed or denied); 

(d) Establish and control the commercial strategy in the United States, including collaborating with Paige to provide services
for CMPBP by both Parties in the United States; 
 (e) [***] 

(f) [***] 

  
 17 

 (g) Provide clinical support and interpretation of results for CMPBP to
ordering physicians, irrespective of whether the order is generated by Paige or Agendia; and 
 (h) Maintain Quality
Management Systems (“QMS”), documentation, technical infrastructure, data, images, etc. per Agendia’s standard operating procedures and to support regulatory inspections, audits and compliance as required by any applicable
Governmental Authority. 
 4.2 Rights and Obligations of Paige. In connection with its rights and obligations under this Agreement, Paige
shall: 
 (a) Co-Develop CMPBP with Agendia to achieve target product performance
and meet regulatory requirements; 
 (b) [***] 

(c) Support Agendia’s United States commercial strategy, including collaborating with Agendia to provide services for
CMPBP by both Parties in the United States; 
 (d) [***] 

(e) Provide clinical support for ordering physicians with interpretation of algorithms or results from the Paige Platform; 

(f) Provide technical support to Agendia and ordering physicians of CMPBP, [***]; and 

(g) Maintain QMS, documentation, technical infrastructure, Patient Data, Customer Data, and any other data, images, etc. per
Paige’s standard operating procedures and to support inspections, audits and compliance as required by any applicable Governmental Authority. 

4.3 Rights and Obligations of Both Parties. In connection with
its rights and obligations under this Agreement, each of Agendia and Paige shall coordinate to: 
 (a) Apply for and obtain
clearance of CMPBP from the U.S. FDA; 
 (b) Apply for and obtain regulatory clearance of CMPBP in other territories,
starting with the European Economic Area (the “EEA”) and applying for a CE mark in the EEA; 
 (c) Share in
the commercial strategy responsibilities and the provision of services for CMPBP in the Territory that is outside the United States, as further detailed below in Section 4.4; 

  
 18 

 (d) Operationalize CMPBP on the Paige Platform and the Agendia Platform,
wherein each Party shall have the following responsibilities in generating results: 
 (i) Customer engagement – [***]

 (ii) Patient Data security – [***] 

(iii) Ordering – [***] 

(iv) Patient Data storage – [***] 

(v) AI analysis – [***] 

(vi) Report generation, storage, and transmission to ordering physician – [***] 

(vii) Billing and reimbursement – [***]; and 

(viii) Regulatory documentation and compliance – [***] 

4.4 Commercialization Plan. 

(a) Agendia shall use Commercially Reasonable Efforts to Commercialize CMPBP in the Territory pursuant to a plan approved by
the JSC in accordance with Section 3.6 (“Commercialization Plan”). Such plan shall include: 

(i) a reasonably detailed description of the key elements of its Commercialization strategy (including messaging, branding,
marketing, advertising, sales force positioning, and pricing); and 
 (ii) a reasonably detailed description and
commercially reasonable timeline of its implementation tactics (including sales force training, promotional activities, distribution channels, and customer service) for such Commercialization strategy for the next Annual Period. 

(b) In connection with the Commercialization Plan, the Parties agree and acknowledge as follows: 

(i) Agendia shall be solely responsible [***]for specific aspects of the commercial strategy for CMPBP including positioning
and messaging, publications, generation of marketing materials, pricing and payor contracts, Third Party non-provider relationships (including but not limited to pharmaceutical companies), and distributor
selection. 

  
 19 

 (ii) Agendia shall also be solely responsible [***]for the commercial
strategy for CMPBP including geographic market selection, target market segments and accounts, marketing and publicity. Agendia shall collaborate with Paige [***]in other aspects of commercial operations such as account-level engagement, contracting
with clinical providers, and service and support for ordering physicians. 
 (iii) If and when the Parties elect to expand
the sale and distribution of CMPBP [***], Agendia and Paige shall be jointly responsible for specific aspects of the commercial strategy for CMPBP including geographic market selection, regulatory jurisdictions, regulatory strategy, target market
segments, account-level strategy, contracting with clinical providers, marketing and publicity. Within the geographies that may be selected by the JSC for commercialization outside of the initial Territory, as of the Effective Date of this
Agreement, Paige shall have a non-exclusive right to distribute CMPBP directly to Third Parties via the Paige Platform. Notwithstanding the foregoing, if either Party determines that it is not commercially
reasonable for such Party to sell or distribute CMPBP in a proposed country or territory, that Party will notify the other Party in writing, and the Parties agree that such Party will not be in material breach of this Agreement for being unable to
sell or distribute such CMPBP in the proposed country or territory. 
 (c) [***]before the anticipated date of the First
Commercial Sale hereunder, Agendia shall prepare and present to the JSC the initial Commercialization Plan for such CMPBP. Following such presentation, Agendia will consider the JSC’s comments regarding the Commercialization Plan and adopt them
as Agendia determines in its sole discretion. 
 (d) Prior to any commercial CMPBP launch and/or the filing with any
Governmental Authority, as part of the Commercialization strategy, the Parties shall enter into a quality agreement in connection with CMPBP and in accordance with the applicable Laws, including but not limited to the International Standards
Organization (“ISO”), the In Vitro Diagnostic Medical Device Regulation (“IVDR”) and the U.S. FDA. 

(e) [***], Agendia shall prepare updates and amendments, as appropriate, to the then-current Commercialization Plan and present
such updates and amendments to the JSC. Any material amendments to the Commercialization Plan (including any acceleration of the First Commercial Sale date for CMPBP, any changes to Product Trademarks, or other material changes) must be approved by
the JSC in accordance with Section 3.6. Upon such approval, each amended Commercialization Plan will be effective and supersede the previous Commercialization Plan as of the date of such approval. 

  
 20 

 (f) For clarity, Agendia has full control and decision-making authority for
the day-to-day conduct of activities implementing the Commercialization Plan [***], unless expressly reserved in this Agreement for the JSC’s determination or
approval; provided that all such decisions must be consistent with the Collaboration’s purpose and objectives, the terms and conditions of this Agreement, and applicable Law. 

4.5 Diligence. Subject to the terms and conditions of this Agreement, the Parties shall use Commercially Reasonable Efforts to Develop
and Commercialize CMPBP in the Field in the Territory in accordance with the Commercialization Plan. 
 4.6 Reporting. Each Party
shall keep the other reasonably informed, through the JSC, of its Commercialization activities concerning CMPBP in the Territory. Without limiting the foregoing, at each regularly scheduled JSC meeting, each Party shall provide the other with a
written report summarizing the significant Commercialization activities performed with respect to each CMPBP since the last JSC meeting, and comparing such activities with the Commercialization Plan for such time period. Such reports must be at a
level of detail sufficient to enable such Party to determine the other’s progress against the applicable Commercialization Plan and compliance with its diligence obligations under Section 4.5. At each such JSC meeting, the Parties shall
discuss the status, progress, and results of Paige’s, Agendia’s and its Distributors’ Commercialization activities. Agendia and Paige shall each promptly respond to the JSC’s questions or requests for additional information
relating to such Commercialization activities. 
 4.7 Extra-Territorial Activities. 

(a) Paige shall not engage in any advertising or promotional activities relating to CMPBP directed primarily to, or solicit
orders from, or deliver (or cause to be delivered) CMPBP to, any customer or user located in any country or jurisdiction outside the Territory. If Paige or any of its Affiliates receive any order for CMPBP for use from a prospective customer or user
located in a country or jurisdiction outside the Territory, Paige shall immediately refer that order to Agendia and shall not accept any such order; Agendia shall use its reasonable discretion to determine whether it can and/or should fulfill such
order for CMPBP. Further, if Agendia or any of its Affiliates or Distributors receive any order for CMPBP for use from a prospective customer or user located in a country or jurisdiction outside the Territory, Agendia shall also use its reasonable
discretion to determine whether it can and/or should fulfill such order for CMPBP. 
 (b) Without limiting
Section 4.7(a), Paige acknowledges that Agendia and its Affiliates and Distributors have the right to Commercialize CMPBP through Digital Media that may be accessible to Persons residing outside the Territory, and such use of Digital Media will
not be deemed to exceed the scope of the licenses granted to Agendia under Section 2.1; provided that (i) such Commercialization activities are primarily directed to supporting Agendia’s Commercialization of CMPBP in the Territory,
and (ii) such Digital Media are chosen with the intent of communicating primarily with Persons residing in the Territory. 

  
 21 

 5. Continuity of Service. 

5.1 Support or Supply of CMPBP. Notwithstanding the provisions of
Section 14, in the event Paige (or its successors) is unable or unwilling to support or supply CMPBP for any reason [***], Agendia shall have the right to terminate this Agreement pursuant to Section 12.6, unless the inability or
unwillingness of Paige to support or supply CMPBP is due to: 
 (a) a Governmental Authority that either (i) fails to
issue an approval or clearance for CMPBP or (ii) prohibits the Development or Commercialization of CMPBP for failure to comply with any requirements under Law, but either such failure is not the result of or due to any negligent act, error or
omission of Paige; 
 (b) a Law barring or enjoining Paige from using the Paige Licensed Patent Rights, the Paige Licensed
Technology or the Paige Background Intellectual Property Rights necessary for the Development or Commercialization of CMPBP, but such application of the Law is not the result of or due to any negligent act, error or omission of Paige; for clarity,
the foregoing excludes any Collaboration Technology or Collaboration Patents both of which are jointly owned by the Parties; or 

(c) a material breach of this Agreement by Agendia which cannot be cured by Agendia during such period; notwithstanding
anything to the contrary in this Agreement, in the event of any dispute between the Parties regarding whether a material breach of Agendia was the cause of Paige being unable or unwilling to support or supply CMPBP, Paige shall use all Commercially
Reasonable Efforts to continue to support or supply CMPBP and/or minimize the cause of Paige’s inability or unwillingness to support or supply CMPBP until such time as the dispute with Paige and Agendia has been resolved. 

5.2 [***] 
 5.3 Deposit.
In connection with the foregoing rights and obligation of the Parties, Paige shall establish, and Agendia shall cover any reasonable cost related to, establishing an escrow account (“Escrow Account”) with [***]
(“Escrow Agent”), in accordance with a mutually agreed upon escrow agreement based upon 

  
 22 

 Escrow Agent’s standard three-party escrow agreement (the “Escrow Agreement”). [***]

 5.4 Release Event. (a) The Escrow Agreement will provide that the Escrow Agent shall release the Deposit [***], in the event
that: 
 (a) [***]; or 

(b) [***] 
 5.5
License to Deposit. Upon the occurrence of the Deposit release event as specified in Section 5.4 and release of the Deposit in accordance with the Escrow Agreement, [***] 

6. Payments. 
 6.1
Revenue Sharing. The Parties shall share the Total Payments Received for CMPBP as set forth in this Section 6.1 (“Revenue Sharing”). Customers shall be sourced via either the Agendia Platform or the Paige Platform;
provided, however, commercial orders must be placed through the customer portal of Agendia (which can be embedded or linked to the back-end of the Paige Platform) to ensure appropriate billing. For customer
orders originated by Agendia or Paige: 
 (a) Agendia shall receive [***]; and 

(b) Paige shall receive [***] 

[***] 

  
 23 

 6.2 Milestone Payments. [***] 

6.3 Research and Non-Commercial Use. [***] 

6.4 [***] 
 6.5
Payment; Reports. 
 (a) Payment Terms. [***] 

  
 24 

 (b) Milestone Payment Terms. [***] 

(c) [***] 
 6.6
Late Payments. If any payment or portion thereof is not received by Paige [***], including any disputed amount, Agendia shall pay to Paige interest on the overdue payment from the date such payment was due to the date of actual payment at the
lower of [***] 
 6.7 Taxes. Revenue Sharing, Milestone Payments and other sums payable under this Agreement are exclusive of taxes.
Agendia is responsible for all sales, use, excise, and value added taxes, and any other similar taxes, duties, and charges of any kind imposed by any federal, state, or local Governmental Authority on any amounts payable by Agendia hereunder, (other
than any taxes imposed on, or with respect to, Paige’s income, revenues, gross receipts, personnel, or real or personal property, or other assets) and shall pay all such sums payable hereunder free and clear of all deductions and withholdings
whatsoever, unless the deduction or withholding is required by Law. If any deduction or withholding is required by Law, Agendia may deduct the amount of the withholding from the payment it otherwise would have made to Paige under this Agreement and
shall include in the report required pursuant to Section 6.5(c) the amount deducted under this Section 6.7. Agendia shall have no liability for taxes of any kind due and owing by Paige; Paige shall be liable for all such taxes. 

  
 25 

 6.8 Records and Audit. 

(a) Commencing [***] after [***] and throughout the Term and the Continuity of Service Period, [***]. Any such audit and Third
Party auditor will be subject to the confidentiality obligations set forth in this Agreement and all information and materials made available in connection with such review will be Paige’s Confidential Information. 

(b) Paige shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit Agendia to
confirm the achievement of Milestone Events. Paige shall keep such books and records [***] following the Annual Period to which they pertain, or such longer period of time as may be required by applicable law. Upon reasonable prior notice to Paige,
such records may be inspected during regular business hours for the sole purpose of verifying the achievement of the Milestone Events [***] following the notice of any such achievement of a Milestone Event. All information and materials made
available in connection with such audit will be Paige’s Confidential Information. 
 (c) Paige shall maintain complete
and accurate development books and records for each CMPBP in sufficient detail in relation to this Agreement for the purposes of supporting regulatory filings, compliance, and audits only. Upon reasonable prior notice to Paige, [***], Agendia may
inspect the non- proprietary portions of such records on-site at Paige’s place of business. Paige shall maintain such books and records for a time period as may be required by applicable Law. 

(d) Agendia shall maintain complete and accurate books and records, including books of account in accordance with generally
accepted accounting principles, in sufficient detail in relation to this Agreement to permit Paige to determine Agendia’s compliance with this Agreement, including diligence with respect to the Revenue Sharing and other payments payable to
Paige under this Agreement. Agendia shall keep such books and records [***], or such longer period of time as may be required by applicable Law. 

  
 26 

 Upon reasonable prior notice to Agendia, such records may be inspected during regular
business hours at such place or places where such records are customarily kept by an independent certified public accountant (the “Auditor”), mutually agreed to by both Parties, for the sole purpose of verifying the accuracy of the
financial reports furnished by Agendia or of any payments made, or required to be made, by Agendia pursuant to this Agreement. All information and materials made available to or otherwise obtained or prepared by or for the Auditor in connection with
such audit will be Agendia’s Confidential Information. Prior to conducting the audit, the Auditor must enter into a written agreement containing confidentiality and non-disclosure obligations at least as
restrictive as those provided in Section 8. Such audits will be limited to once per Annual Period and once with respect to records covering any specific time period. The Auditor shall not disclose Agendia’s Confidential Information to
Paige, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Agendia or the amount of payments by Agendia under this Agreement. If the final result of the audit reveals an undisputed
underpayment or overpayment, the underpaid or overpaid amount must be settled [***]after the Auditor’s report and any underpayment shall be considered a late payment under Section 6.6. Paige shall bear the full cost of such audit unless
such audit reveals an [***], in which case Agendia shall reimburse Paige for the costs of such audit. 
 7. Intellectual
Property Rights. 
 7.1 Background Technology. 

(a) Agendia agrees and acknowledges that the Background Intellectual Property Rights of Paige includes the Paige Platform and
Paige Breast Biomarkers, and all Paige Background Intellectual Property Rights that are the sole and exclusive property of Paige, except as provided in Section 10.2(i) and subject only to the rights of Agendia set forth herein. Notwithstanding
the foregoing, except as otherwise provided in Sections 2.6 and 5, Paige shall not be obligated to disclose any of its Background Intellectual Property Rights, including, but not limited to, its algorithms and any underlying code of its Background
Intellectual Property Rights. All improvements, modifications, derivatives or enhancements made by or on behalf of Paige to the Paige Platform not related to the Agendia Platform shall constitute part of the Paige Platform and be the exclusive
property of Paige. 
 (b) Paige agrees and acknowledges that the Background Intellectual Property Rights of Agendia includes
the Agendia Platform, and all Agendia Background Intellectual Property Rights, are the sole and exclusive property of Agendia, except as provided in Section 10.3(i). Notwithstanding the foregoing,

  
 27 

 
except as otherwise provided in Section 2.6, Agendia shall not be obligated to disclose any of its Background Intellectual Property Rights, including its algorithms. All improvements,
modifications or enhancements to the Agendia Platform not related to the Paige Platform shall constitute part of the Agendia Platform and be the exclusive property of Agendia. 

(c) Each Party acknowledges that the Background Intellectual Property Rights of the other Party contains valuable trade secrets
and Confidential Information of the respective Party and its Affiliates, and accordingly each Party agrees that neither it nor any of its Affiliates (or in the case of Agendia, its Distributors or Sublicensees) shall, during the Term of this
Agreement or at any time thereafter: (a) modify or create derivative works of the other Party’s Background Intellectual Property Rights; (b) except as otherwise expressly permitted by this Agreement, distribute, transmit, disclose or
otherwise make available the other Party’s Background Intellectual Property Rights to any other Person via license or sublicense; or (c) decompile, disassemble, decrypt, extract or otherwise reverse engineer or attempt to derive the source
code of any part of the other Party’s Background Intellectual Property Rights. 
 7.2 Collaboration Data
and Technology. 
 (a) Subject to compliance with HIPAA and any other applicable Laws, the
Development Data and Customer Data shall be jointly owned by the Parties and shall be Confidential Information of both Parties which shall only be disclosed upon mutual agreement in writing; provided that each Party shall retain (i) sole
ownership of any data it owned prior to the effective date of the Existing Agreement or the Effective Date of this Agreement and (ii) sole ownership of its own Background Intellectual Property Rights which may be included in any such results or
generated data, without any license to the other Party herein. 
 (b) Each Party shall promptly disclose to the other Party
all Collaboration Technology arising from the activities of such Party. 
 (c) The Parties will jointly own all right, title,
and interest in and to any Collaboration Technology and any Patent Rights Covering such Collaboration Technology (“Collaboration Patents”). For the avoidance of doubt, Collaboration Patents shall be subject to certain
limitations on use by Paige as detailed in Section 10.4. The inventorship, authorship, or other origination of Collaboration Technology will be determined by United States patent, copyright, or other applicable intellectual property Law.
Subject to Section 2.7 [***], the licenses granted under Section 2.1 and 2.2 and Section 5 (Continuity of Service), neither Party will be free to practice, license, assign, and otherwise exploit the Collaboration Technology or
Collaboration Patents, without the consent from the other Party, such consent not to be unreasonably withheld, delayed or denied; provided, however, that Section 7.4 will govern the enforcement and defense of the Collaboration Technology and
Collaboration Patents and the allocation of any recoveries therefrom. 

  
 28 

 (d) Each Party shall fully cooperate and take all further actions, as the
other Party may reasonably request and at the requesting Party’s expense, to effectuate the allocation of ownership set forth in this Section 7.1. Without limiting the foregoing, each Party shall ensure that each of its employees, agents,
and independent contractors (including, in the case of Agendia, its Distributors or its Sublicensees) performing Collaboration activities, before commencing such activities, is bound by written invention assignment and confidentiality obligations,
including to: (i) promptly report any invention, discovery, or other Intellectual Property Rights invented, created, conceived, developed, or otherwise made by such employee, agent, or independent contractor; (ii) presently assign to the
applicable Party all of their right, title, and interest in and to any such invention, discovery, or other Intellectual Property Right; (iii) cooperate in the preparation, filing, prosecution, maintenance, and enforcement of any Patent Right
Covering any such invention; and (iv) perform all acts and execute, acknowledge, and deliver any and all documents, required for effecting the obligations and purposes of this Section 7.2. 

(e) Neither Party shall incorporate the Intellectual Property Rights of the other Party in any patent filing made by such Party
without the written consent of the other Party. 
 7.3 Patent Filings. 

(a) The JSC will jointly select and approve outside counsel (“Patent Counsel”) prior to
incurring any Collaboration Patent expenses. As between the Parties, subject to Section 7.3(c), with respect to Collaboration Patents, Agendia has the first right, in its discretion, to prepare, file, and prosecute all patent applications and
maintain all issued patents related to Collaboration Patents. Agendia shall bear all costs and expenses incurred in connection with such prosecution and maintenance; provided that Paige shall reimburse Agendia [***] of such expenses within
[***]after receipt of an invoice with respect to any prosecution and maintenance activities reasonably necessary to ensure that a Valid Claim of a Collaboration Patent rights covers CMPBP, as determined by the JSC. The Parties agree that
(i) Agendia shall not spend a sum in excess of an amount to be determined by the JSC regarding the Collaboration Patents, and (ii) in order to optimize the quality and control the costs of the Collaboration Patents, via the JSC, the
Parties shall collaborate in relation to the instructions to be given to Patent Counsel regarding the filings, territories, and overall prosecution of the Collaboration Patents and to any other matters relevant to the Collaboration Patents, which
collaboration shall include planning of the patenting process, the sharing of information (including commenting on documentation) and meeting with Patent Counsel or independently of the Patent Counsel as may be necessary for that purpose . 

  
 29 

 (b) If Agendia intends to forego, abandon, or cease filing, prosecution or
maintenance of any Collaboration Patent right, Agendia shall provide prior notice to Paige of such intention (which notice must be given reasonably in advance of the next deadline to take any action necessary to maintain existing rights in any such
Collaboration Patent right). Upon Paige’s written election [***] after such notice from Agendia, Agendia shall permit Paige to assume prosecution and maintenance of such Collaboration Patent right at its own expense and using patent counsel of
its choosing. Upon notice, at the discretion of Paige, Agendia shall transfer to Paige any ownership interest in such Collaboration Patent to Paige and Paige shall assume the prosecution and maintenance of such Collaboration Patent right at its own
expense and using patent counsel of its own choosing. If Paige does not notify Agendia of its election [***], Agendia may continue or discontinue prosecution and maintenance of such Collaboration Patent right in its discretion. 

(c) If Paige intends to forego, abandon or cease providing assistance to Agendia in the prosecution and maintenance of any
Collaboration Patent ([***]), Paige shall provide prior notice to Agendia of such intention (which notice must be given reasonably in advance of the next deadline to allow Agendia to take any action necessary to maintain or amend existing rights in
any such Collaboration Patent right). Upon notice, at the discretion of Agendia, Paige shall transfer to Agendia any ownership interest in such Collaboration Patent to Agendia and Agendia shall assume the prosecution and maintenance of such
Collaboration Patent right at its own expense and using patent counsel of its own choosing. 
 (d) Each Party shall, and
shall cause its Affiliates and Representatives to, provide all reasonable assistance and cooperation in connection with prosecution and maintenance activities under this Section 7.3, including by making its employees, agents, and independent
contractors reasonably available and executing any necessary documents or instruments, including powers of attorney. 
 7.4
Enforcement of Licensed and Collaboration Technology. 

(a) Notification. If either Party becomes aware of any known or suspected infringement or misappropriation by a Third
Party of any Licensed Technology (including any Collaboration Technology), or any pending or threatened declaratory judgment, opposition, or similar action or proceeding alleging the invalidity, unenforceability, or
non-infringement of any Licensed Patent Right (including any Collaboration Patent), such Party shall promptly notify the other Party and provide the other Party with all information available to it regarding
such activity or allegation. 
 (b) Enforcement Rights. As between Paige and Agendia, Agendia shall
initiate and control any legal proceeding or take other appropriate action against any infringement or misappropriation of, or to defend against any challenge to, any Collaboration Technology (each, an “Action”) at its own expense
and as it reasonably determines appropriate. Paige may be represented in any such Action by counsel of its choosing at its own expense. If, [***], Agendia does not undertake an Action to abate the infringement or misappropriation, then Paige shall
have the right to pursue such Action. 

  
 30 

 (c) Cooperation. At the request and expense of the Party pursuing the
Action (the “Lead Party”), the other Party shall provide reasonable assistance and cooperation in connection therewith. The Lead Party shall keep the other Party reasonably informed of the status of any such Action and, to the
extent deemed necessary or advisable by the Parties’ counsel, the Parties shall enter into a common interest agreement wherein the Parties agree to their shared, mutual interest in such Action’s outcome. If a Party is deemed a necessary
party or otherwise required under Law to join any Action initiated by the Lead Party or if the failure of a Party to become a party to such Action would risk dismissal thereof, such Party shall execute all documents and perform such other acts as
may be reasonably required to permit the Action to be initiated or conducted (including being named as a party in such Action before a court or tribunal). If a Party is required to be joined as a party in any Action initiated by the Lead Party, then
such Party shall waive any objection to such joinder on the grounds of personal jurisdiction, venue, forum non conveniens or any other legal or equitable theory. 

(d) Settlement. The Lead Party may enter into a settlement, consent judgment, or other voluntary final disposition
thereof without the other Party’s consent; provided that notice of such potential settlement or other disposition is provided to the other Party so that the other Party can reasonably determine that it does not require any payment or other
liability or admission by, nor becoming subject to injunctive or other relief by, the other Party and could not otherwise reasonably be expected to adversely affect the other Party, any of the rights granted hereunder, or the scope or enforceability
of the Collaboration Technology. Any other settlement, consent judgment, or voluntary final disposition of any Action requires the prior written consent of such Party, which consent shall not be unreasonably withheld, conditioned, or delayed. 

(e) Recoveries. Any recoveries resulting from any Action (including by settlement or other disposition) first will be
applied to reimburse Paige and Agendia for their reasonable expenses and legal fees incurred in the conduct of such proceedings, and any remaining recoveries will be allocated equally (50/50) between the Parties. 

(f) Exploitation of Collaboration Technology and
Collaboration Patents. Except as provided in Section 5.2, and subject to Sections 2.7, 8, 9, and 10.4 following any expiration or termination of this Agreement or the end of any Continuity of Service Period, either Party shall
be free to exploit its rights in the Collaboration Technology and Collaboration Patents as it sees fit in its sole discretion without any obligation to notify or account to the other Party; provided, however, neither Party shall have the right to
use the other Party’s Confidential Information, Background Intellectual Property Rights or Licensed Technology without the prior written consent of such other Party. Notwithstanding the foregoing, neither Party shall have the right to
sublicense to any Third Party any of its rights under the Collaboration Technology or Collaboration Patents without the prior written consent of such other Party. 

  
 31 

 7.5 Defense of Third Party Intellectual Property Claims. Each Party shall promptly
notify the other Party upon becoming aware of any actual or threatened claim that the Development or Commercialization of CMPBP infringes or misappropriates the Intellectual Property Rights (including Trademarks) of a Third Party in the Field (each,
a “Third Party IP Claim”). Each Party may defend itself from any such Third Party IP Claim brought against such Party or its Affiliates or licensees (or in the case of Agendia, Distributors) at its own expense and with
counsel of its choosing; provided, however, that Section 7.4 will govern the right to assert a counterclaim of infringement or misappropriation of any Licensed Technology, and Section 7.6 will govern the right to assert a counterclaim of
infringement of any Product Mark. Each Party shall keep the other Party reasonably informed of all material developments in connection with any Third Party IP Claim, and the other Party shall consult with and offer reasonable assistance to the Party
defending against such Third Party IP Claim, at the defending Party’s cost and expense. 
 7.6 Product Marks. 

(a) Ownership. Agendia may select the Trademarks (other than the Paige Marks) to be used in connection with the
Commercialization of CMPBP hereunder (collectively, the “Product Marks”). As between the Parties, Agendia will solely own all right, title, and interest in all Product Marks, and all goodwill accruing from Agendia’s or any of
its Distributors’ use of any Product Mark under this Agreement will inure solely to the benefit of Agendia. Agendia has sole control, at its expense and in its discretion, over the prosecution, registration, maintenance, enforcement, and
defense of the Product Marks. 
 (b) All use of the Paige Marks by Agendia and its Affiliates or Distributors must comply
with Paige’s reasonable and customary usage guidelines and quality standards communicated in writing to Agendia and will be subject to Paige’s review and approval 

(c) All use of the Product Marks by Paige and its Affiliates must comply with Agendia’s reasonable and customary usage
guidelines and quality standards communicated in writing to Paige and will be subject to Agendia’s review and approval. 

(d) Any CMPBP developed under this Agreement shall be marked and marketed by Product Marks as well as marked and marketed as
“Powered by Paige”. 
 8. Confidentiality; Publicity and Publications. 

8.1 Confidentiality Obligations. Each Party acknowledges that it may receive or gain access to the other Party’s Confidential
Information during the Collaboration. Except as provided in Section 8.2 or otherwise agreed in writing by the Parties, each Party, as the receiving Party of the other Party’s Confidential Information, shall, [***]: 

  
 32 

 (a) use at least the same standard of care to protect and safeguard the
confidentiality of the disclosing Party’s Confidential Information as the receiving Party uses to protect its own Confidential Information (but no less than reasonable care); and 

(b) not use or disclose, nor permit to be used or accessed, the disclosing Party’s Confidential Information for any
purpose other than to exercise the receiving Party’s rights or perform its obligations under this Agreement. 
 8.2 Exceptions.
Notwithstanding the foregoing obligations of confidentiality and restrictions on use, the receiving Party may disclose the disclosing Party’s Confidential Information: 

(a) to the receiving Party’s employees, agents, or independent contractors who (i) have a need to know such
Confidential Information to assist the receiving Party or act on its behalf in accordance with Section 8.1(b); and (ii) are bound by written agreements containing confidentiality and non-disclosure
obligations at least as restrictive as those set forth in Section 8.1; provided that the receiving Party shall ensure compliance with, and be liable for any breach of, Section 8.1 by any such employees, agents, or independent contractors;

 (b) to the extent necessary to comply with a court order or other applicable Law, including regulations promulgated by
security exchanges; provided that the receiving Party shall provide prompt notice of such required disclosure to the disclosing Party and cooperate with the disclosing Party’s efforts to obtain a protective order, confidential treatment, or
other limitation on such required disclosure; and 
 (c) to actual or prospective acquirers, licensees (including, in the
case of Agendia, its Distributors), investors, lenders, and other financial or commercial partners (and to their respective advisors, agents, and representatives) to the extent strictly necessary for evaluating or carrying out a transaction with
such Persons, in each case under written obligations of confidentiality and non-disclosure at least as restrictive as those set forth in Section 8.1. 

8.3 Equitable Relief. Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon
unauthorized disclosure, use, or transfer of its Confidential Information, monetary damages may not be a sufficient remedy for any breach of this Section 8. Therefore, in addition to all other remedies available at Law, a Party is entitled to
seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Section 8 in accordance with Section 13.4. 

  
 33 

 8.4 Press Release; Public Announcements.
The Parties shall issue a joint press release in form and substance reasonably acceptable to each Party within [***]. Following the issuance of such initial joint press release announcing this Agreement, neither Party shall issue any press release,
communicate with the media, or make any other public statement (orally or in writing) concerning the subject matter of this Agreement without the prior written consent of the other Party (which may not be unreasonably withheld, conditioned, or
delayed), except if and to the extent such Party determines, based on the advice of counsel, that it is required to make any public disclosure or filing regarding the subject matter of this Agreement (“Required Disclosure”): (a) by
applicable Law; (b) pursuant to any rules or regulations of any securities exchange of which the securities of such Party or any of its Affiliates are listed or traded; or (c) in connection with enforcing its rights under this Agreement.
In each case pursuant to clauses (a) or (b) of this Section 8.4, the Party making any Required Disclosure shall consult with the other Party regarding the substance of the Required Disclosure (including any provisions of this Agreement to
be redacted) and provide the other Party a reasonable opportunity (taking into account any legally mandated time constraints) to review and comment on the content of the Required Disclosure prior to its publication or filing. Following the initial
joint press release announcing this Agreement, each Party may disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party, and only those terms of the Agreement which have already
been publicly disclosed in accordance herewith. 
 8.5 Publications. Agendia shall have the lead role in any publication of the
results and data generated from the Collaboration; provided, however, Agendia shall reasonably consider suggestions for such publications from Paige and shall not publish without Paige’s prior written consent, which shall not to be unreasonably
withheld, denied or delayed. Any such publication shall be subject to the provisions of this Agreement relating to confidentiality and non- disclosure, and shall be consistent with academic standards. [***]prior to the submission of a publication,
Agendia shall submit the publication to Paige for review and comment, which shall be provided to Agendia [***]prior to the proposed submission date for publication. If Paige believes that any publication includes Confidential Information of Paige,
Paige will notify Agendia and Agendia will remove all references to such Confidential Information prior to publication, presentation, or use, unless approved in writing by Paige on a
case-by-case basis. 
 9. [Reserved]. 

10. Representations and Warranties; Covenants. 

10.1 Mutual Representations, Warranties and Covenants. Each Party represents, warrants and covenants to the other that: 

(a) it is duly organized, validly existing, and in good standing under the Laws of its jurisdiction of incorporation,
organization, or chartering, and has the full power and authority to enter into this Agreement and to perform its obligations; 

(b) the execution of this Agreement by such Party’s Representative whose signature is set forth at the end hereof has been
duly authorized by all necessary corporate action of such Party; 

  
 34 

 (c) when executed and delivered by such Party, this Agreement constitutes
the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms; 
 (d)
the execution, delivery, and performance of this Agreement by such Party does not violate, conflict with, require consent under, or result in any breach of or default under (i) any applicable Law or (ii) the provisions of any contract,
instrument, or understanding to which it is a party or by which it is bound; 
 (e) it shall not use any Collaboration
Technology or data or materials stemming from any license granted by the other Party to train or validate other products or biomarkers or to permit such data or materials to become integrated into other products. For the avoidance of doubt, nothing
in this section 10.1(e) shall in any way limit or restrict Paige’s use of any improvements, modifications, derivatives, or enhancements made to Paige Background Intellectual Property Rights; 

(f) it has the legal authority to use and transfer any data necessary to carry out its duties and obligations under this
Agreement, including the ability to use and transfer the data anticipated under this Agreement, and it complies, as applicable, with privacy and security Laws in the applicable Territory, including but not limited to HIPAA in the United States and,
its implementing regulations and other applicable federal and state laws and regulations safeguarding the privacy and security of identifiable information; 

(g) that neither it nor any person or entity employed or engaged by it, including without limitation its officers, directors,
employees, or agents who provide services in connection with this Agreement (“Personnel”), are currently: 

(i) excluded, debarred, suspended or otherwise ineligible to participate in federal health care programs as defined in 42
U.S.C. Sec. 1320a-7b or from federal procurement or non-procurement activities as defined in Executive Order 12689 (collectively “Ineligible”); (ii)
debarred or suspended by the U.S. FDA or under the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335(a), as amended, or any similar state law or regulation (collectively “Debarred”) or (iii) convicted of a criminal
offense that falls within the ambit of 42 U.S.C. Sec 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible (“Convicted”); and that it will not
utilize any Ineligible, Debarred, or Convicted Personnel to provide any services hereunder. 
 10.2 Additional
Representations and Warranties of Paige. Paige represents and warrants to the Agendia that, as of the Effective Date: 

(a) the patents and patent applications identified on Schedule 1.72 are all the Patent Rights Controlled by Paige that
(i) Cover any Paige Licensed Know- How or (ii) are necessary for the Commercialization of CMPBP in the Field in the Territory; 

  
 35 

 (b) it has the right to grant the rights and licenses granted to Agendia
hereunder, and it has not granted, and is not under any obligation to grant, to any Third Party any license, lien, option, encumbrance, or other contingent or non- contingent right, title, or interest in or to the Paige Licensed Patent Rights or
Paige Licensed Know-How that conflicts with the rights and licenses granted to Agendia hereunder; 

(c) to Paige’s knowledge, there are no Trademark rights in any word mark owned or possessed by any Third Parties that
would be infringed by the Commercialization of CMPBP using the Paige Marks in the Territory; 
 (d) there is no settled,
pending, or, to Paige’s knowledge, threatened litigation, claim, or proceeding alleging (i) that any Paige Licensed Patent Right is invalid or unenforceable or (ii) that the practice of any Paige Licensed Patent Right or the
Development or Commercialization of CMPBP in the Field in the Territory does or would infringe, misappropriate, or otherwise violate any Patent Right or Know-How of any Third Party; or (iii) any product
liability claim involving CMPBP; 
 (e) it has no knowledge after reasonable investigation of any factual, legal, or other
reasonable basis for any litigation, claim, or proceeding described in Section 11.2(d); 
 (f) Paige has complied in all
material respects with all applicable Laws in connection with the prosecution of the Paige Licensed Patent Rights, including, with respect to any issued patents and pending patent applications, any disclosure requirements of the United States Patent
and Trademark Office, and has timely paid all filing and renewal fees payable with respect thereto; 
 (g) the Development of
CMPBP has been conducted in all material respects in compliance with all applicable Laws and neither Paige nor any of its Affiliates has received notice of, or is subject to, any adverse inspection, investigation, penalty, or other compliance or
enforcement action relating to CMPBP that could reasonably be expected to have a material adverse effect on the Commercialization of CMPBP in the Field in the Territory; 

(h) it will use Commercially Reasonable Efforts to supply and support Agendia with CMPBP throughout the Term; and 

(i) Except as provided in Schedule 10.2(i), 

(i) there is no other agreement between Paige or any of its Affiliates and any Third Party pursuant to which Paige or its
Affiliates has in-licensed any Patent Rights or Know-How that are necessary or useful for the Development or Commercialization of CMPBP in the Field; 

  
 36 

 (ii) Paige represents and warrants (x) that the In-License Agreement listed in Schedule 10.2(i) is in full force and effect, (z) that Paige shall provide written notice to Agendia [***]prior to the expiration of such
In-License Agreement or [***] of the issuance of a notice of termination of such In-License Agreement by either party to the other; and (y) that in the event of an
expiration or termination of such In-License Agreement, at the discretion of Agendia, Paige shall use Commercially Reasonable Efforts to assist Agendia in negotiating a separate license with the In-Licensor of such In-License Agreement; and 

(iii) No written notice of default or termination has been received or given under such
In-License Agreement, and to Paige’s knowledge, there is no act or omission by Paige that would provide a right for the In-Licensor to terminate such In-License Agreement. 
 10.3 Additional Representations and
Warranties of Agendia. Agendia represents and warrants to Paige that, as of the Effective Date: 

(a) the patents and patent applications identified on Schedule 1.7 are all the Patent Rights Controlled by Agendia that
(i) Cover any Agendia Licensed Know-How or (ii) are necessary for the Commercialization of CMPBP in the Field in the Territory; 

(b) it has the right to grant the rights and licenses granted to Paige hereunder, and it has not granted, and is not under any
obligation to grant, to any Third Party any license, lien, option, encumbrance, or other contingent or non-contingent right, title, or interest in or to the Agendia Licensed Patent Rights or Agendia Licensed
Know-How that conflicts with the rights and licenses granted to Paige hereunder; 

(c) it has the right and the authority necessary to transmit, collect, use, and process Customer Data under this Agreement for
the Parties to support and supply CMPBP in the Field in the Territory; 
 (d) to Agendia’s knowledge, there are no
Trademark rights in any word mark owned or possessed by any Third Parties that would be infringed by the Commercialization of CMPBP using the Product Marks in the Territory; 

(e) there is no settled, pending, or, to Agendia’s knowledge, threatened litigation, claim, or proceeding alleging
(i) that any Agendia Licensed Patent Right is invalid or unenforceable or (ii) that the practice of any Agendia Licensed Patent Right or the Development or Commercialization of CMPBP in the Field in the Territory does or would infringe,
misappropriate, or otherwise violate any Patent Right or Know-How of any Third Party; or (iii) any product liability claim involving CMPBP; 

(f) it has no knowledge after reasonable investigation of any factual, legal, or other reasonable basis for any litigation,
claim, or proceeding described in Section 10.3(d); 

  
 37 

 (g) Agendia has complied in all material respects with all applicable Laws
in connection with the prosecution of the Agendia Licensed Patent Rights, including, with respect to any issued patents and pending patent applications, any disclosure requirements of the United States Patent and Trademark Office, and has timely
paid all filing and renewal fees payable with respect thereto; 
 (h) the Development of CMPBP has been conducted in all
material respects in compliance with all applicable Laws and neither Agendia nor any of its Affiliates has received notice of, or is subject to, any adverse inspection, investigation, penalty, or other compliance or enforcement action relating to
CMPBP that could reasonably be expected to have a material adverse effect on the Commercialization of CMPBP in the Field in the Territory; 

(i) Except as provided in Schedule 10.3(i) 

(i) there is no other agreement between Agendia or any of its Affiliates and any Third Party pursuant to which Agendia or its
Affiliates has in-licensed any Patent Rights or Know-How that are necessary or useful for the Development Commercialization of CMPBP in the Field in the Territory; and

 (ii) Agendia represents and warrants (x) that the In-License Agreement
listed in Schedule 10.3(i) is in full force and effect, (y)no written notice of default or termination has been received or given under such In- License Agreement, and (z) to Agendia’s knowledge, there is no act or omission by Agendia that
would provide a right for the In-Licensor to terminate such In-Licence Agreement, but that in the event of any termination or expiration, Agendia shall provide written
notice to Paige at least ninety (90) days prior to the expiration of such In-License Agreement or within three (3) days of the issuance of a notice of termination of such In-License Agreement by either party to the other. 
 10.4 Covenants of
Each Party. 
 (a) Non-Solicitation – [***] 

(b) Non-Competition – [***]—Agendia. [***], Agendia shall not work with a
Third Party who is a direct competitor of Paige in digital pathology or computation pathology in the Field to Develop or research, or have Developed or researched on its behalf, any Competing Product that does not include the participation of Paige.

 (c) Non-Competition – [***] – Paige. [***], Paige shall not, either
alone or in conjunction with a Third Party: 

  
 38 

 (i) use any aspect of the Agendia Platform, the Agendia Background
Intellectual Property Rights, the Agendia Intellectual Property Rights, the Confidential Information of Agendia, the Collaboration Technology, the Development Data, the Customer Data and/or the CMPBP in connection with (i) the further
Development and Commercialization of CMP, CBP, or CMPBP or (ii) other Paige products; 
 (ii) Develop or research, or
have Developed or researched on its behalf, any Competing Product; or 
 (iii) engage in any Commercialization or non-commercial activities involving CMP, CBP, or CMPBP, [***], or Collaboration Technology that does not include the participation and the prior written consent of Agendia. For the avoidance of doubt, Paige
disclosed to Agendia Paige’s prior work on certain breast cancer biomarkers; [***] that are covered by the claims of patent rights of Paige or are the specific subject of a Paige research and development program, which is independent of Agendia
(“Paige Breast Biomarkers”), which as individual diagnostic tests shall not be considered Competing Products with CMP, CBP or CMPBP for the purpose of this Agreement. 

(d) Non-Competition [***]. 

(i) [***] 

(ii) [***] 

  
 39 

 10.5 Compliance with Laws. Each Party shall comply and shall ensure that its
employees, agents, and independent contractors comply with all applicable Laws in the exercise of its rights and performance of its obligations under this Agreement, including, without limitation, all Laws relating to required permits, licenses,
filings, certifications, and other approvals required by the FDA or any similar state or local or foreign Law in the Territory; the Anti-Kickback provisions of the Social Security Act, 42 U.S.C. §
1320a-7b(b), and the relevant regulations at 42 C.F.R. Part 1001 (“Healthcare Fraud and Abuse Laws”); the False Claims Act, 31 U.S.C. § 3729; and Laws relating to the confidentiality and
security of personal and medical data, including but not limited to HIPAA and any other laws and/or regulations relating to the maintenance, use, transmission or other activity concerning patient records and confidentiality of personal and medical
data. Each Party represents and warrants that it has not been excluded from any U.S. federal or state health care program for violation of any Health Care Fraud and Abuse Laws or the False Claims Act or applicable regulations. Without limiting the
foregoing, each Party shall, at its sole expense, obtain and maintain during the Term, and for Agendia during any Continuity of Service Period, all certifications, credentials, authorizations, licenses, and permits necessary to conduct that portion
of its business relating to Development and Commercialization of CMPBP, as applicable. 
 10.6 Disclaimer. EXCEPT AS EXPRESSLY
PROVIDED IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,
SAFETY, ABSENCE OF ERRORS OR OMISSIONS, ACCURACY, OR COMPLETENESS (INCLUDING OF ANY CONFIDENTIAL INFORMATION, BACKGROUND INTELLECTUAL PROPERTY RIGHTS, OR MATERIALS, TECHNICAL ASSISTANCE, TECHNIQUES, OR PRACTICES DISCLOSED OR PROVIDED HEREUNDER), THE
PROSPECTS OR LIKELIHOOD OF SUCCESS (FINANCIAL OR OTHERWISE) OF THE COLLABORATION OR THE PRODUCTS, OR THE VALIDITY, SCOPE, OR NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS. Notwithstanding anything to
the contrary in this Agreement, neither Party makes any representation, warranty, or covenant, either express or implied, that CMPBP, if Commercialized, will achieve any Milestone Events or any level of Total Payments Received or that any other
results will be achieved with respect to Commercialization of CMPBP hereunder. 
 11. Indemnification. 

11.1 Indemnification by Agendia. Agendia shall indemnify, defend, and hold harmless Paige and its Affiliates, and each of Paige’s
and its Affiliates’ respective officers, directors, employees, agents, successors, and assigns (each, a “Paige Indemnified Party”) from and against all Losses arising out of or resulting from any claim, suit, action, or
proceeding by any Third Party (“Indemnified Claim”) relating to: 
 (a) any breach by Agendia of any
representation, warranty, covenant, or obligation under this Agreement; 
 (b) the gross negligence or willful misconduct, or
any failure to comply with applicable Law, of any employee, agent, or independent contractor of Agendia or any of its Distributors in connection with this Agreement; 

  
 40 

 (c) the infringement, misappropriation, or other violation of Third Party
Intellectual Property Rights based on use by a Paige Indemnified Party of the Agendia Background Intellectual Property Rights or Confidential Information; 

(d) the infringement or other violation of any Third Party’s Trademark rights by use of any Product Trademark; or 

(e) any product liability, personal injury, or property damage resulting from Third Party use of CMPBP. 

except in each case to the extent any such Losses are covered by Paige’s indemnification obligations under Section 11.2. 

11.2 Indemnification by Paige. Paige shall indemnify, defend, and hold harmless Agendia and its Affiliates,
and each of Agendia’s and its Affiliates’ respective officers, directors, employees, agents, successors, and assigns (each, a “Agendia Indemnified Party”) from and against all Losses arising out of or resulting from any
Indemnified Claim relating to: 
 (a) any breach by Paige of any representation, warranty, covenant, or obligation under this
Agreement; 
 (b) the gross negligence or willful misconduct, or any failure to comply with applicable Law, of any employee,
agent, or independent contractor of Paige in connection with this Agreement; 
 (c) the infringement, misappropriation, or
other violation of any Third Party Intellectual Property Rights based on use by an Agendia Indemnified Party of Paige’s Background Intellectual Property Rights or Confidential Information; or 

(d) any product liability, personal injury, or property damage resulting from Third Party use of CMPBP. 

except in each case to the extent any such Losses are covered by Agendia’s indemnification obligations under Section 11.1. 

11.3 Indemnification Procedure. An Indemnified Party shall promptly notify the Party from whom it is seeking indemnification
(“Indemnifying Party”) upon becoming aware of an Indemnified Claim with respect to which the Indemnifying Party is obligated to provide indemnification under this Section 11. The Indemnifying Party shall promptly
assume control of the defense and investigation of the Indemnified Claim, with counsel of its own choosing, and the Indemnified Party shall reasonably cooperate with the Indemnifying Party in connection therewith, in each case at the Indemnifying
Party’s sole cost and expense. The Indemnified Party may participate in the defense of such Indemnified Claim, with counsel of its own choosing and at its own cost and expense. The Indemnifying Party shall not settle any Indemnified Claim on
any terms or in any manner that adversely affects the rights of any Indemnified Party without the Indemnified Party’s prior written consent (which consent may not be unreasonably withheld, conditioned, or delayed). If the Indemnifying Party
fails or refuses to assume control of the defense of an Indemnified Claim, the Indemnified Party may, but is not obligated to, defend against such 

  
 41 

 Indemnified Claim, including settling such Indemnified Claim after giving notice to the Indemnifying Party,
in each case in such manner and on such terms as the Indemnified Party may deem appropriate. The Indemnified Party’s failure to perform any obligation under this Section 11.3 will not relieve the Indemnifying Party of its obligations under
this Section 11, including with respect to any Losses, except to the extent that the Indemnifying Party can demonstrate that it has been materially prejudiced as a result thereof. 

11.4 Insurance. During the Term and for a period of [***]after expiration or termination of this Agreement, each Party shall maintain,
at its expense, commercial general liability insurance in commercially reasonable amounts and with appropriate coverage, including product liability, personal injury, bodily injury, and property damage, for the Development, Commercialization, and
use of CMPBP and contractual liability coverage for its indemnification obligations under this Agreement. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.
For clarity, such insurance will not limit either Party’s obligations or liability (including with respect to its indemnification obligations) hereunder. Each Party shall ensure that any Distributor performing activities in connection with this
Agreement has proper and adequate general liability insurance to cover its risks with respect to the other Party for damages mentioned above. 

11.5 Limitation of Liability. 

(a) TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR
ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR ENHANCED DAMAGES, OR FOR ANY LOSS OF ACTUAL OR ANTICIPATED PROFITS (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT
(INCLUDING NEGLIGENCE OR STRICT LIABILITY), STATUTE, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH DAMAGE WAS FORESEEABLE AND WHETHER EITHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. 
 (b) EACH PARTY ACCEPTS THAT NOTHING IN THIS AGREEMENT, INCLUDING THE LIMITATIONS IN THIS SECTION 11 EXCLUDES
OR LIMITS EITHER PARTY’S LIABILITY FOR: (A) DEATH OR PERSONAL INJURY CAUSED BY SUCH PARTY; (B) LOSSES ARISING OUT OF OR RELATING TO A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8; (C) LOSSES ARISING OUT OF OR
RELATING TO FRAUDULENT MISREPRESENTATION, GROSS NEGLIGENCE, OR WILLFUL MISCONDUCT OF A PARTY, OR IN THE CASE OF AGENDIA, ANY OF ITS DISTRIBUTORS IN PERFORMING UNDER THIS AGREEMENT; (D) BREACH OF PRIVACY OR DATA PROTECTION OBLIGATIONS AND CLAIMS
FROM CUSTOMERS ARISING FROM SUCH BREACH; (E) ANY INFORMATION SECURITY INCIDENT AND CLAIMS FROM CUSTOMERS ARISING FROM SUCH INCIDENT; (F) ITS INDEMNITY OBLIGATIONS; OR (G) OTHERWISE TO THE EXTENT SUCH LIMITATION IS NOT OTHERWISE PERMITTED
BY LAW. 

  
 42 

 (c) EXCEPT AS SET FORTH IN SECTION, IN NO EVENT SHALL THE AGGREGATE
LIABILITY OF EITHER PARTY AND ITS REPRESENTATIVES, FOR ANY AND ALL CLAIMS ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, WHETHER ARISING IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, WARRANTY, STATUTE OR OTHERWISE, WHETHER AT
LAW OR IN EQUITY, WILL NOT EXCEED [***] 
 12. Term and Termination. 

12.1 Term. 

(a) This Agreement is effective as of the Effective Date and, unless earlier terminated in accordance with this
Section 12 or as expressly provided elsewhere in this Agreement, will continue in full force and effect until ten (10) years after the First Commercial Sale of CMPBP in the Territory (the “Term”). 

(b) Agendia may, at its option and in its sole discretion, renew this Agreement for an additional [***] upon written notice to
Paige [***]prior to expiration of the Term. 
 (c) Upon expiration of the Term (but not earlier termination of this
Agreement) and unless this Agreement is renewed pursuant to Section 12.1(b), the rights and obligations of the Parties under this Agreement will terminate, except as expressly provided in Section 12.9. 

12.2 Termination for Material Breach. Either Party may terminate this Agreement in its
entirety immediately upon notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party [***] after notice of such breach from the non-breaching Party; provided, however, that the Cure Period may be extended at the non-breaching Party’s discretion [***] if the breaching Party has begun good faith
efforts to remedy such breach within the initial Cure Period and provides to the non-breaching Party a written plan to cure such breach within such Cure Period extension. If the alleged breaching Party
disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such Dispute [***] after receipt of notice of such breach, then
the other Party may not terminate this Agreement under this Section 12.2 unless and until an arbitral panel in accordance with Section 13.3 determines that the alleged breaching Party has materially breached the Agreement and such Party
fails to cure such breach within the applicable cure period set forth above commencing on the date of such 

  
 43 

 decision. For clarity, a material breach would constitute a breach of any of the obligations, terms,
conditions and covenants of this Agreement or covenants by a Party, which materially and substantially affects the Development, distribution and Commercialization of CMPBP contemplated by this Agreement and results in circumstances which may or do
(i) render any right vested in a Party by the terms of this Agreement ineffective; or (ii) adversely affect or restrict or frustrate the ability of any Party to observe and perform in a timely manner its obligations under this Agreement or
(iii) adversely affects the legality, validity, binding nature or enforceability of this Agreement. 
 12.3 Termination for
Insolvency. Either Party may terminate this Agreement in its entirety immediately upon notice to the other Party if such other Party: (a) is dissolved or liquidated or takes any corporate action for such purpose; (b) becomes insolvent;
(c) files or has filed against it a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law; (d) makes or
seeks to make a general assignment for the benefit of creditors; or (e) applies for or has a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of
its property or business; and (f) any such insolvency event (a)-(e) is not dismissed, set-aside, or vacated [***]. 

12.4 [***] 
 12.5
Agendia’s Right to Terminate for Convenience. Agendia may terminate this Agreement in its entirety without cause by providing [***]notice to Paige of such termination. 

12.6 Agendia’s Right to Terminate for
Failure to Supply. Agendia may terminate this Agreement in its entirety immediately upon notice to Paige, if Paige materially breaches this Agreement by being unable or unwilling to support or supply CMPBP to
Agendia for any reason for a period [***], unless the inability or unwillingness of Paige to support or supply CMPBP is due to the circumstances referenced in Section 5.1(a) – (c) herein. 

12.7 Paige’s Right to Terminate for Convenience. Paige may terminate this Agreement in its entirety without cause by
providing [***]notice to Agendia of such termination. 
 12.8 Effect of Termination. Upon a termination of this Agreement, the
following will apply: 
 (a) Confidential Information. Each Party shall promptly [***]after the effective date of
termination, return to the other Party, or delete or destroy, all relevant records and materials in such Party’s possession or control containing Confidential Information and/or Background Intellectual Property Rights of the other Party,
including any copies, 

  
 44 

 extracts or portions thereof; provided that such Party may keep one copy of such materials
to the extent required to comply with applicable laws, rules and regulations and subject to continuing confidentiality obligations in accordance with Section 8. Upon request by a Party, such other Party shall certify in writing it has complied
with the foregoing. The foregoing shall also apply if the other Party undergoes a Change in Control that results in a controlling interest being given to a direct competitor of such Party. 

(b) Restrictive Covenants. Each Party shall be subject to the applicable restrictive covenants set forth in Section 10.4
herein. 
 (c) [***] 

  
 45 

 (d) Aggregate Payment. In the event Agendia commits a material breach of
this Agreement pursuant to Section 12.2 herein and fails to cure such breach, and only if Paige has achieved all Milestone Events and not materially breached this Agreement, Agendia shall pay Paige the balance, if any, of the Aggregate Payment.
For clarity, upon termination this Agreement under this Section 12.2, if the aggregate consideration paid to Paige under this Agreement equals or exceeds such amount, Paige shall not be entitled to any further consideration upon termination.
If, however, Paige has not yet received an amount equal to the Aggregate Payment, Paige shall be paid any remaining balance to reach the outstanding threshold [***]. For the avoidance of doubt, such payment does not affect any other rights and
remedies Paige may have under this Agreement. 
 (e) Termination for Convenience by Paige. [***] 

(f) Termination for Convenience by Agendia—[***] 

(i) if by the date of notice of such termination [***], Agendia shall pay Paige [***]; 

(ii) if by the date of notice of such termination, Paige failed to achieve any one of the Milestone Events, due to no material
fault on the part of Agendia, Agendia shall be free to develop the CMP, CBP, or CMPBP with a Third Party or develop any other digital emulation of MammaPrint and/or BluePrint, independently or with any other Third Party, but shall not be permitted
to use any of Paige’s Confidential Information or Paige Background Intellectual Property Rights in doing so; 
 (iii)
if by the date of notice of such termination, Paige has achieved each of the Milestone Events and not materially breached this Agreement, Paige shall be entitled to the balance, if any, of the Aggregate Payment; and 

(iv) [***] 

(g) Licenses; Distribution Agreements. Except as provided in Section 2.1(h) herein, all licenses granted under this
Agreement by one Party to the other Party will automatically terminate. In connection with the exclusive license granted by Paige under Section 2.1(h), during any Continuity of Service Period, Agendia shall be free to appoint any Distributor
without the consent of Paige. 

  
 46 

 12.9 Survival. The expiration or termination of this Agreement or end of a Continuity
of Service Period provided in this Agreement will not relieve the Parties of any obligations accruing before the effective date of any of the foregoing events. The rights and obligations of the Parties set forth in Section 1 (Definitions),
Section 2.1(h) (Paige License Grant), Section 2.3 (Mutual Data License Grant), Section 2.7 [***], Section 5 (Continuity of Service), Section 6.8 (Records and Audit), Section 7 (Intellectual Property Rights),
Section 8 (Confidentiality; Publicity), Section 10.1 (Mutual Representations, Warranties and Covenants), Section 10.2 (Additional Representations and Warranties of Paige), Section 10.3 (Additional Representations and Warranties
of Agendia), Section 10.4 (Covenants of Each Party), Section 10.5 (Compliance with Laws), Section 11 (Indemnification), Section 12.8 (Effect of Termination), Section 14 (Dispute Resolution) and Section 16
(Miscellaneous), and any right, obligation, or required performance of the Parties under this Agreement that, by its express terms or nature and context is intended to survive any expiration or termination of this Agreement, or end of a Continuity
of Service Period provided in this Agreement, will survive any such expiration or termination of this Agreement, or end of a Continuity of Service Period. 

13. Dispute Resolution. 

13.1 Objective. The Parties recognize that disputes, controversies, or claims arising out of or in connection with this Agreement, or
its interpretation, breach, termination, or invalidity (each a “Dispute”), may from time to time occur during the Term. It is the Parties’ objective to establish procedures to facilitate the resolution of Disputes in an
expedient manner by mutual cooperation and without resorting to litigation. To accomplish this objective, subject to Section 13.4, the Parties shall follow the procedure set forth in this Section 13 to resolve any Dispute. Either Party may
initiate the dispute resolution procedure of this Section 13 by giving the other Party notice (“Dispute Notice”). 

13.2 Escalation to Executives. The Parties shall attempt in good faith to initially resolve any Dispute by negotiation between the
Chief Executive Officer for Paige and the Chief Executive Officer for Agendia (the “Executives”). [***]after a Dispute Notice provided to a Party in accordance with Section 13.1, the Executives shall meet in person, or by
teleconference, at a mutually agreeable time and place, and thereafter as often as they reasonably deem necessary, to attempt in good faith to resolve the Dispute. If the Executives are unable to resolve such Dispute [***]after the Dispute Notice,
then either Party may submit the Dispute for resolution by binding arbitration in accordance with Section 13.3. 
 13.3
Arbitration. Any Dispute a Party submits for arbitration pursuant to Section 13.2 will be resolved through binding arbitration in accordance with the International Institute for Conflict Prevention and Resolution Rules for Non-Administered Arbitration, as amended from time to time (the “Rules”), except where they conflict with these provisions, in which case these provisions will control, and the substantive law
specified in Section 16.12(a). Any Dispute in which either Party seeks [***] in damages will be resolved by an arbitral tribunal consisting of three (3) arbitrators, one (1) of whom will be designated by each Party in accordance with
the Rules, and a third arbitrator who will chair the tribunal and who will be selected as provided in the Rules. Any other Dispute will be submitted to a sole arbitrator, appointed pursuant to the Rules. The arbitrator(s) will render a written
opinion setting forth findings of fact and conclusions of law with the reasons 

  
 47 

 therefor stated. No arbitral tribunal will have the power to award damages excluded under this Agreement
pursuant to Section 11.5 and any arbitral award that purports to award such damages is void. Arbitration pursuant to this Section 13.3 will be governed by the Federal Arbitration Act, 9 U.S.C. §§
1-16, and judgment upon any award rendered by the arbitrators in accordance with this Section 13.3 may be entered in any court of competent jurisdiction. The arbitration proceedings for all Disputes will
be conducted in Wilmington, Delaware or any other venue as the Parties may mutually agree. Except in a proceeding to enforce the results of the arbitration or as otherwise required by applicable Law, all aspects of the arbitration, including the
existence of the arbitration, the arbitral proceedings, the submissions made by the Parties, and the decisions made by the arbitral tribunal, including its awards to the extent not already in the public domain, will be treated as Confidential
Information. Each Party will bear its own attorneys’ fees, costs, and disbursements arising out of the arbitration, and will pay an equal share of the fees and costs of the arbitrator; provided, however, the arbitrator(s) will be authorized to
determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys’ fees, costs, and disbursements, or the fees and costs of the administrator and the
arbitrator(s). 
 13.4 Equitable Remedies; Court Proceedings. Notwithstanding the foregoing or anything to the
contrary in this Agreement, either Party may initiate court proceedings in any court of competent jurisdiction for: 
 (a)
any claim for injunctive or other equitable relief, including specific performance, in the event of an actual or threatened breach by the other Party of any of its obligations under this Agreement, notwithstanding any ongoing discussions between the
Parties or any ongoing arbitration under Section 13.3, and the Parties hereby agree that (i) any such actual or threatened breach would give rise to irreparable harm for which monetary damages would not be an adequate remedy; and
(ii) a Party will be entitled to seek such injunctive or other equitable relief, in addition to any and all other rights and remedies that may be available to such Party at Law or in equity or otherwise in respect of such breach, without the
posting of any bond or other security; or 
 (b) any Dispute concerning the validity, construction, scope, enforceability,
infringement, or misappropriation of Patent Rights or other Intellectual Property Rights. 
 13.5 Excluded Matters. For
clarity, and notwithstanding the foregoing or anything to the contrary in this Agreement, (a) if any matter is within the scope of the JSC’s authority, the provisions of Section 3.6 will initially apply with respect to such matter;
and (b) if this Agreement expressly provides that such matter is subject to a Party’s discretion or to a Party’s sole decision-making authority, such matter will not be subject to dispute resolution under this Section 13, but may
be finally determined by such Party in accordance with the terms of this Agreement. 
 13.6 Continued Performance. Each
Party shall continue to perform its obligations under the Agreement pending final resolution of any Dispute unless to do so would be impossible or impracticable under the circumstances. If either Party receives a Dispute Notice, then any associated
time to cure will be stayed pending the resolution of the issue pursuant to this Section 13. 

  
 48 

 13.7 Attorneys’ Fees. In any Dispute for which a Party is
permitted to bring a court proceeding under Section 13.4, the prevailing Party will be entitled to recover its reasonable attorneys’ fees and court costs from the non-prevailing Party. 

14. Force Majeure. Neither Party will be liable or responsible to the other Party, nor be deemed to have defaulted under or breached
this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement (except for either Party’s obligations to make payments when due to the other hereunder), when and to the extent such failure or delay is caused by
or results from events beyond the affected Party’s reasonable control, including acts of God, pandemics, flood, fire, or explosion, war, terrorism, invasion, riot, or other civil unrest, embargoes, or blockades in effect on or after the
Effective Date, national or regional emergency, strikes, labor stoppages or slowdowns, or other industrial disturbances, any passage of Law or governmental order, rule, regulation, or direction, or any action taken by a Governmental Authority,
including imposing an embargo, export or import restriction, quota, or other restriction or prohibition, national or regional shortage of adequate power or telecommunications or transportation facilities or any other similar event (each, a
“Force Majeure Event”). The affected Party shall give notice to the other Party, stating the period of time the occurrence is expected to continue. The affected Party shall use Commercially Reasonable Efforts to end the failure or delay
and ensure the effects of such Force Majeure Event are minimized. The affected Party shall resume the performance of its obligations as soon as reasonably practicable after the removal of the cause. If the affected Party’s failure or delay
remains uncured for a period of one hundred twenty (120) days following notice given by it under this Section 14, either Party may terminate this Agreement upon thirty (30) days’ notice. Unless either Party terminates this Agreement
pursuant to the preceding sentence, all timelines in the Commercialization Plan will automatically be extended for a period up to the duration of the Force Majeure Event. 

15. Assignment. 
 15.1
Except as otherwise expressly provided in this Agreement, neither Party may assign or otherwise transfer all or any of its rights, or delegate or otherwise transfer all or any of its obligations, hereunder without the prior written consent of the
other Party (which consent may not be unreasonably withheld, conditioned, or delayed); provided, however, that either Party may make such an assignment, delegation, or other transfer, in whole or in part, without the other Party’s consent: 

(a) to an Affiliate; provided that the assigning Party shall remain liable and responsible for the performance of all
obligations and compliance with all other terms and conditions of this Agreement by such Affiliate; or 
 (b) in connection
with the transfer or sale to a Third Party of all or substantially all of the business or assets of such Party relating to CMPBP (“Acquirer”), whether by Change of Control, restructuring, sale of business unit or product line
divestiture, or other transaction, and whether this Agreement is expressly assigned or is assumed by the Acquirer by operation of law; provided 

  
 49 

 that, following any such transaction, the Intellectual Property Rights the Acquirer owned or
held before such transaction or thereafter developed outside the Collaboration and without use of or reference to any Confidential Information or Intellectual Property Rights of the other Party or any Collaboration Technology will not be deemed to
be Controlled for purposes of the licenses granted under this Agreement or otherwise affected or encumbered by this Agreement. 
 15.2
Notwithstanding Section 15.1 or anything to the contrary in this Agreement, either Party may withhold its consent, in its discretion, to any assignment, delegation, or other transfer of this Agreement, in whole or in part, whether express or by
operation of Law, to any competitor of such Party, with the exception to a Change of Control of Agendia. 
 15.3 No delegation or other
transfer by a Party will relieve such Party of any of its obligations under this Agreement. Any purported assignment or other transfer in violation of this Section 15 is void. This Agreement is binding upon and inures to the benefit of the
Parties and their respective permitted successors and assigns. 
 16. Miscellaneous. 

16.1 Further Assurances. Each Party shall, upon the reasonable request, of the other Party, promptly execute such documents and perform
such acts as may be necessary to give full effect to the terms of this Agreement. 
 16.2 Relationship of the Parties. The
relationship between the Parties is that of independent contractors. Nothing contained in this Agreement will be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship
between the Parties, and neither Party will have authority to contract for or bind the other Party in any manner whatsoever. 
 16.3
Notices. Each Party shall deliver all notices, requests, consents, claims, demands, waivers, and other communications under this Agreement (each, a “Notice”) in writing and addressed to the other Party at its address set out
below (or to any other address the receiving Party may designate from time to time in accordance with this Section). Each Party shall deliver all Notices by personal delivery, nationally recognized overnight courier (with all fees prepaid),
facsimile or email (with confirmation of transmission), or certified or registered mail (in each case, return receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is effective only (a) upon receipt by
the receiving Party; and (b) if the Party giving the Notice has complied with the requirements of this Section. 
  

			
	If to Agendia:	  	Agendia, Inc.
		  	[***]

  
 50 

			
	 If to Paige:
	  	 PAIGE.AI

		  	[***]

 16.4 Interpretation. For purposes of this Agreement, (a) the words “include,”
“includes,” and “including” will be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; and (c) the words “herein,” “hereof,”
“hereby,” “hereto,” and “hereunder” refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Sections and Schedules refer to the Sections of and Schedules attached to
this Agreement; (y) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (z) to a
statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement is to be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting an instrument or causing any instrument to be drafted. 
 16.5 Headings. The headings in
this Agreement are for reference only and do not affect the interpretation of this Agreement. 
 16.6 Entire Agreement. This
Agreement, together with any other documents incorporated herein by reference and all related Schedules, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein and therein, and supersedes all
prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter, including but not limited, to the Existing Agreement, except as otherwise provided herein. In the
event of any inconsistency between the statements in the body of this Agreement and those in any Schedule or Exhibit or other document, the following order of precedence will govern: (a) first, this Agreement, excluding its Schedules;
(b) second, the Schedules or Exhibits to this Agreement as of the Effective Date; and (c) third, any other documents incorporated herein by reference. 

16.7 Expenses. Except as otherwise expressly provided herein or in any Commercialization Plan, each Party is responsible for all of its
own costs and expenses in performing its obligations under this Agreement and neither Party is obligated to reimburse the other Party for any costs or expenses a Party incurs in performing such obligations. 

16.8 No Third-Party Beneficiaries. This Agreement is for the sole benefit of the Parties and their respective successors and permitted
assigns and nothing herein, express or implied, is intended to or will confer upon any other Person any legal or equitable right, benefit, or remedy of any nature whatsoever, under or because of this Agreement. 

  
 51 

 16.9 Amendment; Modification; Waiver. This Agreement may
only be amended, modified, or supplemented by an agreement in writing signed by each of the Parties. No waiver by any Party of any of the provisions hereof will be effective unless expressly set forth in writing and signed by the waiving Party.
Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power, or privilege arising from this Agreement will operate or be construed as a waiver thereof; nor will any single or partial
exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege. 

16.10 Cumulative Remedies. All rights and remedies provided in this Agreement are cumulative and not exclusive and are in addition to
and not in substitution for any other rights or remedies that may now or subsequently be available at Law or in equity or otherwise. 

16.11 Severability. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such
invalidity, illegality, or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon a determination that any term or other provision
is invalid, illegal, or unenforceable, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to the greatest extent possible. 
 16.12 Governing
Law; Submission to Jurisdiction. 
 (a) This Agreement and all related
documents, and all matters arising out of or relating to this Agreement, are governed by, and construed in accordance with, the laws of the State of Delaware, United States of America, without regard to the conflict of laws provisions thereof to the
extent such principles or rules would require or permit the application of the laws of any jurisdiction other than those of the State of Delaware. 

(b) Any Dispute for which a Party is permitted to bring a court proceeding must be instituted exclusively in the federal courts
of the United States or the courts of the State of Delaware in each case located in the City of Wilmington and County of New Castle, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, or
proceeding. Service of process, summons, notice, or other document by mail to such Party’s address set forth herein will be effective service of process for any suit, action, or other proceeding brought in any such court. 

16.13 Waiver of Jury Trial. Each Party irrevocably and unconditionally waives any right it may have to a trial by jury for any court
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby for which a Party may bring such a court proceeding. 

  
 52 

 16.14 Counterparts. This Agreement may be executed in counterparts, each of which
will be deemed an original, but all of which together will be deemed to be one and the same agreement. A signed copy of this Agreement delivered by email or other means of electronic transmission (to which a PDF copy is attached) will be deemed to
have the same legal effect as delivery of an original signed copy of this Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 53 

 IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the Effective Date. 

 

			
	AGENDIA, INC.
		
	By	 	/s/ Mark Straley
		 	Name: Mark Straley
		 	Title: CEO
	
	 AGENDIA, INC.

		
	By	 	/s/ Brian Dow
		 	Name: Brian Dow
		 	Title: CFO
	
	 PAIGE.AI, INC.

		
	By	 	/s/ Leo Grady
		 	Name: Leo Grady
		 	Title: CEO
	
	 IN CONNECTION WITH SECTION 2.2:

	 ACKNOWLEDGED AND AGREED TO:

	
	 AGENDIA, N.V.

		
	By	 	/s/ Mark Straley
		 	Name: Mark Straley
		 	Title: CEO
	
	 AGENDIA, N.V.

		
	By	 	/s/ Brian Dow
		 	Name: Brian Dow
		 	Title: CFO

  
 54 

 EXHIBIT A 

[***] 

  
 55 

 EXHIBIT B 

Existing Distributors 
 [***]

  
 1 

 Schedule 1.7 

Agendia Licensed Patent Rights 

[***] 

  
 2 

 Schedule 1.72 

Paige Licensed Patent Rights 

[***] 

  
 3 

 Schedule 1.74 

Paige Marks 
 [***] 

  
 1 

 Schedule 10.2(i) 

In-Licensed Patent Rights or Know-How [***] 

[***] 

  
 1 

 Schedule 10.3(i) 

In-Licensed Patent Rights or Know-How [***] 

[***] 

  
 1Document

Exhibit 4.6

			
	

FOURTH SUPPLEMENTAL INDENTURE

between

OFFICE PROPERTIES INCOME TRUST

and

U.S. BANK NATIONAL ASSOCIATION,
as Trustee

Dated as of August 13, 2021

SUPPLEMENTAL TO THE INDENTURE DATED AS OF JULY 20, 2017

________________________

OFFICE PROPERTIES INCOME TRUST

2.400% Senior Notes due 2027

________________________
			
	

This FOURTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of August 13, 2021 between Office Properties Income Trust (formerly known as Government Properties Income Trust), a real estate investment trust organized and existing under the laws of the State of Maryland (the “Company”), having its principal office at Two Newton Place, 255 Washington Street, Suite 300, Newton, Massachusetts 02458-1634, and U.S. Bank National Association, a national banking organization organized and existing under the laws of the United States, as Trustee (the “Trustee”).
RECITALS OF THE COMPANY

The Company (then known as Government Properties Income Trust) and the Trustee are parties to an Indenture, dated as of July 20, 2017 (as from time to time hereafter amended, supplemented or otherwise modified in so far as it applies to the Notes (as defined herein), the “Base Indenture” and, together with this Supplemental Indenture, as amended, supplemented or otherwise modified from time to time, the “Indenture”) to provide for the future issuance of the Company’s senior unsecured debentures, notes or other evidences of indebtedness (the “Securities”), to be issued from time to time in one or more series; and 
Pursuant to the terms of the Base Indenture, the Company desires to provide for the establishment of a series of its Securities, to be known as its 2.400% Senior Notes due 2027, the form and substance of such Securities and the terms, provisions and conditions thereof to be set forth as provided in the Indenture; 
NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH: 
ARTICLE 1

DEFINED TERMS
Section 1.1Terms Defined in Indenture.  Capitalized terms used herein and not defined herein have the meanings ascribed to such terms in the Base Indenture.
Section 1.2Supplemental Definitions.  The following definitions supplement, and, to the extent inconsistent with, replace the definitions in Section 101 of the Base Indenture: 
“Acquired Debt” means Debt of a Person: (i) existing at the time such Person becomes a Subsidiary; or (ii) assumed in connection with the acquisition of assets from such Person, in each case, other than Debt incurred in connection with, or in contemplation of, such Person becoming a Subsidiary or such acquisition.  Acquired Debt is deemed to be incurred on the date of the related acquisition of assets from any Person or the date the acquired Person becomes a Subsidiary.
“Adjusted Total Assets” has the meaning provided in clause (i) of Section 3.1(a) of this Supplemental Indenture.
“Annual Debt Service” as of any date means the maximum amount which is expensed in any 12-month period for interest on Debt of the Company and its Subsidiaries, excluding amortization of debt discounts and deferred financing costs.
“Business Day” means any day other than a Saturday or Sunday or a day on which banking institutions in The City of New York or in the city in which the Corporate Trust Office is located are required or authorized to close.
“Capital Stock” means, with respect to any Person, any capital stock (including preferred stock), shares, interests, participation or other ownership interests (however designated) of such Person and any rights (other than debt securities convertible into or exchangeable for capital stock), warrants or options to purchase any thereof.
“Cash Equivalents” means demand deposits, certificates of deposit or repurchase agreements with banks or other financial institutions, marketable obligations issued or directly and fully guaranteed as to timely payment by the United States of America or any of its agencies or instrumentalities, or any commercial paper or other obligation rated, at time of purchase, “P-2” (or its equivalent) or better by Moody’s Investors Service, Inc. (or any successor thereof) or “A-2” (or its equivalent) or better by Standard & Poor’s Ratings Services, a Standard & Poor’s Financial Services LLC business (or any successor thereof).

“Consolidated Income Available for Debt Service” for any period means Earnings from Operations of the Company and its Subsidiaries plus amounts which have been deducted, and minus amounts which have been added, for the following (without duplication): (i) interest on Debt of the Company and its Subsidiaries; (ii) provision for taxes of the Company and its Subsidiaries based on income; (iii) amortization of debt premium/discount and deferred debt issuance costs; (iv) provisions for gains and losses on properties and property depreciation and amortization; (v) the effect of any noncash charge resulting from a change in accounting principles in determining Earnings from Operations for such period; and (vi) amortization of deferred charges.
“Debt” of the Company or any Subsidiary means, without duplication, any indebtedness of the Company or any Subsidiary, whether or not contingent, in respect of:
(i)borrowed money or evidenced by bonds, notes, debentures or similar instruments;
(ii)borrowed money secured by any Encumbrance existing on property owned by the Company or any Subsidiary, to the extent of the lesser of (x) the amount of indebtedness so secured and (y) the fair market value of the property subject to such Encumbrance;
(iii)the reimbursement obligations, contingent or otherwise, in connection with any letters of credit actually issued (other than letters of credit issued to provide credit enhancement or support with respect to other indebtedness of the Company or any Subsidiary otherwise reflected as Debt hereunder) or amounts representing the balance deferred and unpaid of the purchase price of any property or services, except any such balance that constitutes an accrued expense or trade payable, or all conditional sale obligations or obligations under any title retention agreement;
(iv)the principal amount of all obligations of the Company or any Subsidiary with respect to redemption, repayment or other repurchase of any Disqualified Stock; or
(v)any lease of property by the Company or any Subsidiary as lessee which is reflected on the Company’s consolidated balance sheet as a capitalized lease in accordance with GAAP;
to the extent, in the case of items of indebtedness under (i) through (v) above, that any such items (other than letters of credit) would be properly classified as a liability on the Company’s consolidated balance sheet in accordance with GAAP.  Debt (1) excludes any indebtedness (A) with respect to which a defeasance or covenant defeasance or discharge has been effected (or an irrevocable deposit is made with a trustee in an amount at least equal to the outstanding principal amount of such indebtedness, the remaining scheduled payments of interest thereon to, but not including, the applicable maturity date or redemption date, and any premium or otherwise as provided in the terms of such indebtedness) in accordance with the terms thereof or which has been repurchased, retired, repaid, redeemed, irrevocably called for redemption (and an irrevocable deposit is made with a trustee in an amount at least equal to the outstanding principal amount of such indebtedness, the remaining scheduled payments of interest thereon to, but not including, such redemption date, and any premium) or otherwise satisfied or (B) that is secured by cash or Cash Equivalents irrevocably deposited with a trustee in an amount, in the case of this clause (B), at least equal to the outstanding principal amount of such indebtedness and the remaining scheduled payments of interest thereon and (2) includes, to the extent not otherwise included, any obligation by the Company or any Subsidiary to be liable for, or to pay, as obligor, guarantor or otherwise (other than for purposes of collection in the ordinary course of business), Debt of another Person (other than the Company or any Subsidiary) (it being understood that Debt shall be deemed to be incurred by the Company or any Subsidiary whenever the Company or such Subsidiary shall create, assume, guarantee or otherwise become liable in respect thereof).
“Depositary” has the meaning provided in Section 2.1(d) of this Supplemental Indenture.
“Disqualified Stock” means, with respect to any Person, any Capital Stock of such Person which by the terms of such Capital Stock (or by the terms of any security into which it is convertible or for which it is exchangeable or exercisable), upon the happening of any event or otherwise: (i) matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise (other than Capital Stock which is redeemable solely in exchange for Capital Stock which is not Disqualified Stock or for Subordinated Debt); (ii) is convertible into or exchangeable or exercisable for Debt (other than Subordinated 
2

Debt or Disqualified Stock); or (iii) is redeemable at the option of the holder thereof, in whole or in part (other than Capital Stock which is redeemable solely in exchange for Capital Stock which is not Disqualified Stock or for Subordinated Debt), in each case on or prior to the Stated Maturity of the principal of the Notes.
“Earnings from Operations” for any period means (i) net earnings, excluding (1) gains and losses on sales of investments, (2) extraordinary items, (3) gains and losses on early extinguishment of debt, (4) property valuation losses and (5) equity in the earnings and losses of Equity Method Investments, plus (ii) to the extent not included in net earnings, cash distributions received by the Company or its Subsidiaries from Equity Method Investments, in each case as reflected in the financial statements of the Company and its Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP.
“Encumbrance” means any mortgage, lien, charge, pledge or security interest or other encumbrance.
“Equity Method Investments” means equity securities that at the time of determination: (i) are part of a class of equity securities that is traded on a national or regional securities exchange or a recognized over-the-counter market; (ii) issued by an entity (a) to which the Company’s manager at such time or an Affiliate of the Company’s manager at such time provides management services, (b) that operates in a manner intended to qualify such entity for taxation as a “real estate investment trust” under Sections 856 to 860 of the Internal Revenue Code of 1986, as amended, and (c) that is not a consolidated Subsidiary of the Company; and (iii) are or in any prior period were accounted for in the consolidated financial statements of the Company using the equity method of accounting.
“Fair Value” means, for an Equity Method Investment, the lower of: (i) the original cost of such investment; or (ii) last reported sale price on the exchange or market on which the class of equity securities of which the investment is a part is primarily traded at the time of valuation.
“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board, or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which were in effect on the date of initial issuance of securities pursuant to the Base Indenture (i.e., July 20, 2017).
“Interest Payment Date” with respect to the Notes has the meaning provided in Section 101 of the Base Indenture and Section 2.1(e) of this Supplemental Indenture.
“Issue Date” means August 13, 2021.
“Joint Venture Interests” means assets of the Company and its Subsidiaries constituting an equity investment in real estate assets or other properties, or in an entity holding real estate assets or other properties, jointly owned by the Company and its Subsidiaries, on the one hand, and one or more other Persons not constituting Affiliates of the Company, on the other, excluding any entity or properties (i) which is a Subsidiary or are properties if the co-ownership thereof (if in a separate entity) would constitute or would have constituted a Subsidiary, or (ii) to which, at the time of determination, the Company’s manager at such time or an Affiliate of the Company’s manager at such time provides management services.  In no event shall Joint Venture Interests include equity securities that are part of a class of equity securities that are traded on a national or regional securities exchange or a recognized over-the-counter market or any investments in debt securities, mortgages or other Debt or Equity Method Investments.
“Make-Whole Amount” means the excess, if any, of (i) the aggregate present value as of the date of redemption of each dollar of principal being redeemed and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable in respect of such dollar if such redemption had been made on January 1, 2027, determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (determined on the third Business Day preceding the date such notice of redemption is given) from the date on which such principal and interest would have been payable if such redemption had been made on January 1, 2027 over (ii) the aggregate principal amount of the notes being redeemed. In the case of any redemption of  the notes on or after January 1, 2027, the Make-Whole Amount will equal 
3

zero. The Make-Whole Amount shall be calculated by the Company and set forth in an Officer’s Certificate delivered to the Trustee, and the Trustee shall be entitled to rely on said Officer’s Certificate.
“Notes” means the Company’s 2.400% Senior Notes due 2027, issued under the Indenture, as amended or supplemented from time to time.
“Regular Record Date” with respect to the Notes has the meaning provided in Section 101 of the Base Indenture and Section 2.1(e) of this Supplemental Indenture.
“Reinvestment Rate” means a rate per annum equal to the sum of 0.250% (twenty five one hundredths of one percent), plus the yield on treasury securities at constant maturity under the heading “Week Ending” published in the Statistical Release under the caption “Treasury Constant Maturities” for the maturity (rounded to the nearest month) corresponding to the remaining life to maturity of the notes (which shall be deemed to be January 1, 2027) as of the payment date of the principal being redeemed. If no maturity exactly corresponds to such maturity, yields for the two published maturities most closely corresponding to such maturity shall be calculated pursuant to the immediately preceding sentence and the Reinvestment Rate shall be interpolated or extrapolated from such yields on a straight-line basis, rounding in each of such relevant periods to the nearest month. For purposes of calculating the Reinvestment Rate, the most recent Statistical Release published prior to the date of determination of the Make-Whole Amount shall be used.
“Secured Debt” means Debt secured by an Encumbrance on the property of the Company or its Subsidiaries.
“Significant Subsidiary” means any Subsidiary which is a “significant subsidiary” (within the meaning of Regulation S-X promulgated by the Commission under the Securities Act) of the Company.
“Statistical Release” means the statistical release designated “H.15” or any successor publication which is published daily by the Federal Reserve System and which establishes yields on actively traded United States government securities adjusted to constant maturities or, if such statistical release (or any successor publication) is not published at the time of any determination under the Indenture, then any publicly available source of similar market data used for this purpose in accordance with customary market practice which shall be designated by the Company.
“Subordinated Debt” means Debt which by the terms of such Debt is subordinated in right of payment to the principal of and interest and premium, if any, on the Notes.
“Subsidiary” means any corporation or other Person of which a majority of (1) the voting power of the voting equity securities or (2) the outstanding equity interests of which are owned, directly or indirectly, by the Company or one or more other Subsidiaries of the Company, and which is required to be consolidated in accordance with GAAP. For the purposes of this definition, “voting equity securities” means equity securities having voting power for the election of directors or persons serving comparable functions as directors, whether at all times or only so long as no senior class of security has such voting power by reason of any contingency.
“Total Assets” as of any date means the sum of (i) the Undepreciated Real Estate Assets; (ii) the Fair Value of all Equity Method Investments of the Company and its Subsidiaries; and (iii) all other assets of the Company and its Subsidiaries on such date determined in accordance with GAAP (but excluding accounts receivable and intangibles); provided that the portion of Total Assets attributable to Equity Method Investments of the Company and its Subsidiaries may not exceed 35%.
“Total Unencumbered Assets” as of any date, means the sum of (i) those Undepreciated Real Estate Assets not securing any portion of Secured Debt; (ii) the Fair Value of all Equity Method Investments of the Company and its Subsidiaries not securing any portion of Secured Debt; and (iii) all other assets of the Company and its Subsidiaries not securing any portion of Secured Debt on such date determined in accordance with GAAP (but excluding accounts receivable and intangibles); provided that, in determining Total Unencumbered Assets as a percentage of the aggregate outstanding principal amount of Unsecured Debt of the Company and its Subsidiaries on a consolidated basis for purposes of the covenant set forth in Section 3.1(b) of this Supplemental Indenture, Joint Venture Interests shall be excluded from Total Unencumbered Assets to the extent such Joint Venture Interests would otherwise be included therein; and provided further 
4

that the portion of Total Unencumbered Assets attributable to Equity Method Investments of the Company and its Subsidiaries may not exceed 35%.
“Undepreciated Real Estate Assets” as of any date means the cost (original cost plus capital improvements) of real estate assets of the Company and its Subsidiaries on such date, before depreciation and amortization, determined on a consolidated basis in accordance with GAAP. 
“Unsecured Debt” means any Debt of the Company or its Subsidiaries which is not Secured Debt.
ARTICLE 2

TERMS OF THE NOTES
Section 2.1Terms of the Notes.  Pursuant to Section 301 of the Base Indenture, the Notes shall have the following terms and conditions:
(a)Title.  The Notes shall be in registered form under the Indenture and shall be known as the Company’s “2.400% Senior Notes due 2027.”
(b)Aggregate Principal Amount.  Except (i) as provided in this Section and (ii) for Notes authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Notes pursuant to Section 304, 305, 306, 906 or 1107 of the Base Indenture and except for any Notes which, pursuant to Section 303 of the Base Indenture, are deemed never to have been authenticated and delivered hereunder, the Notes will be limited to an aggregate principal amount of $350,000,000, subject to the right of the Company to reopen such series for issuances of additional Notes having the same terms and conditions as the Notes issued on the Issue Date except for issue date, issue price and, if applicable, the first Interest Payment Date thereon and related interest accrual date.  
(c)Form of Notes.  The Notes (together with the Trustee’s certificate of authentication) shall be substantially in the form of Exhibit A hereto, which is hereby incorporated in and made a part of this Supplemental Indenture.  
(d)Registered Securities in Book Entry Form.   The Notes shall be initially issued in the form of one or more registered Global Securities without coupons (each, a “Global Note”) and shall be deposited with, or on behalf of, The Depository Trust Company (“DTC” and, together with any successor depositary with respect to the Global Notes appointed under the Indenture, the “Depositary”) and registered in the name of DTC’s nominee, Cede & Co.  Unless and until it is exchanged in whole or in part for the individual Notes represented thereby under the circumstances described below, a Global Note may not be transferred except as a whole by a Depositary to its nominee, by a nominee of a Depositary to such Depositary or another nominee of such Depositary, or by a Depositary or its nominee to a successor Depositary or a nominee of such successor.
So long as a Depositary or its nominee is the Holder of a Global Note, such Depositary or its nominee, as the case may be, will be considered the sole owner or Holder of the Notes represented by such Global Note for all purposes under the Indenture.  Except as provided below, owners of a beneficial interest in Notes evidenced by a Global Note will not be entitled to have any of the individual Notes represented by such Global Note registered in their names, will not receive or be entitled to receive physical delivery of any such Notes in definitive form and will not be considered the owners or Holders thereof under the Indenture for any purpose, including with respect to giving of any direction, instructions or approvals to the Trustee hereunder.
A Global Note may be exchanged in whole or in part for individual Notes represented thereby only if (i) the Depositary (A) has notified the Company that it is unwilling or unable to continue as a depositary for such Global Note or (B) has ceased to be a clearing agency registered under the Exchange Act, and in either case a successor depositary shall not have been appointed by the Company within ninety (90) days after such notice is received by the Company or the Company becomes aware of such cessation, respectively, or (ii) there shall have occurred and be continuing an Event of Default with respect to such Global Note and the Security Registrar has received a written request from an owner of beneficial interest in 
5

such Global Note to receive registered Notes.  In any such case, the Company will issue individual Notes in exchange for such Global Note representing such Notes in authorized denominations.
Notwithstanding any provisions of Section 2.1(e) or Section 2.1(f) of this Supplemental Indenture to the contrary, payments of principal, premium, if any, and interest on any Global Note shall be made in accordance with the procedures of the Depositary and its participants in effect from time to time.
(e)Interest and Interest Rate.  The Notes will bear interest at a rate of 2.400% per annum, from August 13, 2021 (or, in the case of Notes issued after August 13, 2021, from the date designated by the Company in connection with such issuance), or from the immediately preceding Interest Payment Date to which interest has been paid or duly provided for, payable semi-annually in arrears on February 1 and August 1 of each year, commencing February 1, 2022 (each of which shall be an “Interest Payment Date”), or if such day is not a Business Day, on the next succeeding Business Day, to the Persons in whose names the Notes are registered in the Security Register at the close of business on the Regular Record Date for such interest, which shall be January 15 or July 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date (each, a “Regular Record Date”).
(f)Principal Repayment; Currency.  The Stated Maturity of the principal of the Notes is February 1, 2027; provided, however, the Notes may be earlier redeemed at the option of the Company as provided in Section 2.1(g) of this Supplemental Indenture.  The principal of each Note payable at its Maturity shall be paid against presentation and surrender thereof at the Corporate Trust Office, in such coin or currency of the United States of America as at the time of payment is legal tender for the payment of public or private debts.  
(g)Redemption at the Option of the Company. The Notes will be subject to redemption in whole at any time or in part from time to time prior to their maturity at the option of the Company upon not less than fifteen (15) nor more than sixty (60) days’ notice to each Holder of Notes to be redeemed at its address appearing in the Security Register, or, in the case of any Global Note, in accordance with the procedures of the Depositary and its participants in effect from time to time, at a Redemption Price equal to the sum of (i) the principal amount of the Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including, the applicable Redemption Date and (ii) the Make-Whole Amount, if any (it being understood that if the Notes are redeemed on or after January 1, 2027, the Make-Whole Amount equals zero).  
On or before 11:00 a.m. Eastern Time on any Redemption Date, the Company shall deposit with the Trustee or with a Paying Agent (or, if the Company is acting as its own Paying Agent, segregate and hold in trust as provided in Section 1003 of the Base Indenture) an amount of money sufficient to pay the Redemption Price of, and accrued and unpaid interest on, all the Notes which are to be redeemed on such Redemption Date.  If the Company instructs the Trustee in writing to send the notice of redemption in the name of and at the expense of the Company as provided in Section 1104 of the Base Indenture, the Company shall provide the Trustee with such written instruction at least five (5) Business Days (or such shorter time as the Trustee may agree) prior to the date such notice of redemption is to be sent. 
(h)Notices.  Notices to the Company shall be directed to it at Two Newton Place, 255 Washington Street, Suite 300, Newton, Massachusetts 02458-1634, email: cbilotto@rmrgroup.com, Attention: President; notices to the Trustee shall be directed to it at One Federal Street, 3rd Floor, Boston, Massachusetts 02110, email: david.doucette@usbank.com, Attention: Corporate Trust Department, Re: Office Properties Income Trust 2.400% Senior Notes due 2027, or as to either party, at such other address as shall be designated by such party in a written notice to the other party.  All notices and communications (other than those sent to Holders of the Notes) shall be deemed to have been duly given at the time delivered by hand, if personally delivered; five (5) calendar days after mailing if sent by registered or certified mail, postage prepaid (except that a notice of change of address shall not be deemed to have been given until actually received by the addressee); when receipt is acknowledged, if sent by e-mail; and the next Business Day after timely delivery to the courier, if sent by overnight air courier guaranteeing next day delivery.
(i)Legal Holidays.  If any Interest Payment Date, Redemption Date or the Stated Maturity for the principal of the Notes falls on a day that is not a Business Day, the payment otherwise payable on such day will be due and payable on the next succeeding Business Day, and no interest will accrue thereon for the period from and after such Interest Payment Date, Redemption Date or Stated Maturity, as the case may be, through such next succeeding Business Day.  The provisions of this Section 2.1(i) shall supersede and replace Section 113 of the Base Indenture with respect to the Notes.
6

ARTICLE 3

ADDITIONAL COVENANTS
Section 3.1Additional Covenants of the Company.  In addition to the covenants of the Company set forth in Article Eight and Article Ten of the Base Indenture, the Holders of the Notes shall have the benefit of the following covenants:
(a)Limitations on Incurrence of Debt.
(i)The Company will not, and will not permit any Subsidiary to, incur any additional Debt if, immediately after giving effect to the incurrence of such additional Debt and the application of the proceeds therefrom, the aggregate principal amount of all outstanding Debt of the Company and its Subsidiaries on a consolidated basis determined in accordance with GAAP is greater than 60% of the sum of (without duplication):
(A)Total Assets as of the end of the fiscal quarter covered by the Company’s Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, most recently filed with the Commission (or, if such filing is not permitted or required under the Exchange Act, with the Trustee) (such quarter, the “Latest Completed Fiscal Quarter”) prior to the incurrence of such additional Debt; and
(B)the purchase price of any real estate assets or mortgages receivable acquired, and the amount of any securities offering proceeds received (to the extent that such proceeds were not used to acquire real estate assets or mortgages receivable or used to reduce Debt), by the Company or any Subsidiary since the end of such Latest Completed Fiscal Quarter, including those proceeds obtained in connection with the incurrence of such additional Debt.
For purposes of this Supplemental Indenture, the sum of (A) and (B) above is the Company’s “Adjusted Total Assets.”
(ii)The Company will not, and will not permit any Subsidiary to, incur any additional Secured Debt if, immediately after giving effect to the incurrence of such additional Secured Debt and the application of the proceeds therefrom, the aggregate principal amount of all outstanding Secured Debt of the Company and its Subsidiaries on a consolidated basis determined in accordance with GAAP is greater than 40% of Adjusted Total Assets.
(iii)The Company will not, and will not permit any Subsidiary to, incur any additional Debt if, immediately after giving effect to the incurrence of such additional Debt and on a pro forma basis, including the application of the proceeds therefrom, the ratio of Consolidated Income Available for Debt Service to Annual Debt Service for the four consecutive fiscal quarters most recently ended prior to the date on which such additional Debt is to be incurred is less than 1.5 to 1.0, and calculated on the assumptions that:
(A)such Debt and any other Debt incurred by the Company and its Subsidiaries on a consolidated basis since the first day of such four-quarter period and the application of the proceeds therefrom, including to refinance other Debt, had occurred at the beginning of such period;
(B)the repayment, retirement or other discharge of any other Debt by the Company and its Subsidiaries on a consolidated basis since the first day of such four-quarter period had occurred at the beginning of such period (except that, in making such computation, the amount of Debt under any revolving credit facility shall be computed based upon the average daily balance of such Debt during such period);
(C)in the case of Acquired Debt or Debt incurred in connection with or in contemplation of any acquisition, including any Person becoming a Subsidiary, since the first day of such 
7

four-quarter period, the related acquisition had occurred as of the first day of such period with appropriate adjustments with respect to such acquisition being included in such pro forma calculation; and
(D)in the case of any acquisition or disposition by the Company and its Subsidiaries on a consolidated basis of any asset or group of assets since the first day of such four-quarter period, whether by merger, stock purchase or sale, or asset purchase or sale, such acquisition or disposition or any related repayment of Debt had occurred as of the first day of such period with the appropriate adjustments with respect to such acquisition or disposition being included in such pro forma calculation. 
If the Debt giving rise to the need to make the foregoing calculation or any other Debt incurred after the first day of the relevant four-quarter period bears interest at a floating interest rate, then, for purposes of calculating the Annual Debt Service, the interest rate on such Debt will be computed on a pro forma basis as if the average interest rate which would have been in effect during the entirety of such four-quarter period had been the applicable rate for the entirety of such period.
(b)Maintenance of Total Unencumbered Assets.  The Company and its Subsidiaries will at all times maintain Total Unencumbered Assets of not less than 150% of the aggregate outstanding principal amount of the Unsecured Debt of the Company and its Subsidiaries on a consolidated basis in accordance with GAAP.
ARTICLE 4

OTHER PROVISIONS
Section 4.1Restatement and Amendment of Certain Provisions of Section 101 of the Base Indenture.    (a) The provisions of Section 101(a) of the Base Indenture, as applied to the Notes, are restated in their entirety and shall be deemed to read as follows in lieu of the provisions set forth therein:
“(a) the terms defined in this Article have the meanings assigned to them in this Article and include the plural as well as the singular, and the term “Notes” has the meaning assigned to it in the Supplemental Indenture and includes the plural as well as the singular;”
(b) Section 101 of the Base Indenture, as applied to the Notes, is further amended by adding the following defined term in its appropriate alphabetical position:
““Supplemental Indenture” means the Fourth Supplemental Indenture to this Indenture, dated as of August 13, 2021, by and between the Company and the Trustee, as the same may be amended or supplemented from time to time.”
Section 4.2Sinking Funds not Applicable.  Section 501(c) of the Base Indenture shall not be applicable to the Notes.
Section 4.3Restatement of Section 501(d) of the Base Indenture. The provisions of Section 501(d) of the Base Indenture, as applied to the Notes, are restated in their entirety and shall be deemed to read as follows in lieu of the provisions set forth therein:
“(d)    a default in the performance of, or breach of, any covenant of the Company in this Indenture (not including a covenant a default in whose performance or whose breach is elsewhere in the Indenture specifically dealt with or which has been expressly included in this Indenture solely for the benefit of a series of Securities other than that series), and continuance of such default or breach for a period of sixty (60) days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of more than 25% in principal amount of the Outstanding Securities of that series, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or”
8

Section 4.4Restatement of Section 501(e) of Base Indenture. The provisions of Section 501(e) of the Base Indenture, as applied to the Notes, are restated in their entirety and shall be deemed to read as follows in lieu of the provisions set forth therein:
“(e)    the Company or one of its Significant Subsidiaries, if any, pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case, or (iii) consents to the appointment of a Custodian of it or for all or substantially all of the Company’s or such Significant Subsidiary’s property; or”
Section 4.5Restatement of Section 501(f) of Base Indenture. The provisions of Section 501(f) of the Base Indenture, as applied to the Notes, are restated in their entirety and shall be deemed to read as follows in lieu of the provisions set forth therein:
“(f)    a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: (i) is for relief against the Company or one of its Significant Subsidiaries, if any, in an involuntary case, (ii) appoints a Custodian of the Company, or such Significant Subsidiary, or for all or substantially all of the Company’s or such Significant Subsidiary’s property, or (iii) orders the liquidation of the Company, or such Significant Subsidiary, and the order or decree remains unstayed and in effect for ninety (90) days; or”
Section 4.6Additional Events of Default.  In accordance with Section 501(g) of the Base Indenture, the following shall also constitute an “Event of Default” with respect to the Notes:
“(1)    a default under any bond, debenture, note or other evidence of indebtedness of the Company, or under any mortgage, indenture or other instrument of the Company (including a default with respect to Securities issued under the Indenture other than the Notes) under which there may be issued or by which there may be secured any indebtedness of the Company (or by any Subsidiary, the repayment of which the Company has guaranteed or for which the Company is directly responsible or liable as obligor or guarantor), whether such indebtedness now exists or shall hereafter be created, which default shall constitute a failure to pay an aggregate principal amount exceeding $25,000,000 of such indebtedness when due and payable after the expiration of any applicable grace period with respect thereto and shall have resulted in such indebtedness in an aggregate principal amount exceeding $25,000,000 becoming or being declared due and payable prior to the date on which it would otherwise have become due and payable; provided, however, that if there is no other senior unsecured indebtedness of the Company, the maturity of which would be accelerated by a default under any of the Company’s indebtedness in an aggregate principal amount of $25,000,000 or less, the references to $25,000,000 in this clause (c) shall be replaced by the lesser of the indebtedness cross-default amount contained in the Company’s then existing senior unsecured credit facility or such other senior unsecured indebtedness, as long as such amount is greater than $25,000,000, not to exceed $50,000,000.  Such default shall not be an Event of Default if the indebtedness shall have been discharged, or such acceleration shall have been rescinded or annulled, within a period of ten (10) days after there shall have been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of more than 25% in aggregate principal amount of the Outstanding Notes a written notice specifying such default and requiring the Company to cause such indebtedness to be discharged or cause such acceleration to be rescinded or annulled and stating that such notice is a “Notice of Default” under the Indenture;”
Section 4.7Amounts due on Acceleration.  Notwithstanding any provisions to the contrary in the Base Indenture, upon any acceleration of the Notes under Section 502 of the Base Indenture, the amount immediately due and payable in respect of the Notes shall equal the outstanding principal amount thereof, plus accrued and unpaid interest thereon.
Section 4.8Applicability of Satisfaction and Discharge.  Article Four of the Base Indenture applies to the Notes, except for the proviso at the end of Section 401(a).
Section 4.9Applicability of Defeasance and Covenant Defeasance.  Article Thirteen of the Base Indenture applies to the Notes, except for the proviso in the first sentence of Section 1304(a).
9

ARTICLE 5

EFFECTIVENESS
This Supplemental Indenture shall be effective for all purposes as of the date and time this Supplemental Indenture has been executed and delivered by the Company and the Trustee in accordance with Article Nine of the Base Indenture.  As supplemented hereby, the Base Indenture is hereby confirmed as being in full force and effect.
ARTICLE 6

MISCELLANEOUS
Section 6.1Separability.  In the event any provision of this Supplemental Indenture shall be held invalid or unenforceable by any court of competent jurisdiction, such holding shall not invalidate or render unenforceable any other provision hereof or any provision of the Indenture.
Section 6.2Construction of Terms.  To the extent that any terms of this Supplemental Indenture or the Notes are inconsistent with the terms of the Base Indenture, the terms of this Supplemental Indenture or the Notes shall govern and supersede such inconsistent terms.
Section 6.3Effect of Headings. The section headings herein are for convenience only and shall not affect the construction hereof.
Section 6.4Governing Law.  This Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York. 
Section 6.5Counterparts and Electronic Signatures.  This Supplemental Indenture may be executed in several counterparts, each of which shall be an original and all of which shall constitute but one and the same instrument.  The words “execution,” “signed,” “signature,” and words of like import in this Supplemental Indenture or in any other certificate, agreement or document related to this Supplemental Indenture or the Notes shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, “pdf”, “tif” or “jpg”) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based recordkeeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code. The Company agrees to assume all risks arising out of the use of using digital signatures and electronic methods to submit communications to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk of interception and misuse by third parties.
[Signature Page Follows]
10

IN WITNESS WHEREOF, the Company and the Trustee have caused this Supplemental Indenture to be executed as an instrument under seal in their respective corporate names as of the date first above written. 
OFFICE PROPERTIES INCOME TRUST 
By: /s/ Matthew C. Brown             
Name:  Matthew C. Brown
Title:    Chief Financial Officer and Treasurer
U.S. BANK NATIONAL ASSOCIATION, as
Trustee 
By: /s/ David W. Doucette             
Name:  David W. Doucette
Title:    Vice President

[Signature Page: Fourth Supplemental Indenture]

EXHIBIT A
FORM OF NOTE
[Form of Face of Security]
[Insert Applicable Legends]
OFFICE PROPERTIES INCOME TRUST
2.400% Senior Notes due 2027
															
	No. ____
				$ ___________

					
					
					
					
					
					
					
					
					

Office Properties Income Trust (formerly known as Government Properties Income Trust), a real estate investment trust duly organized and existing under the laws of Maryland (the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to _____________________________, or registered assigns, the principal sum of ___________________ Dollars ($_____________) [(as the same may be revised from time to time on the Schedule of Exchanges of Interests in the Global Security attached hereto)] on February 1, 2027, and to pay interest thereon from _______, 20__ or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on February 1 and August 1 in each year, commencing February 1, 2022 at the rate of 2.400% per annum, until the principal hereof is paid or made available for payment.  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest, which shall be January 15 or July 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than ten (10) days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.
Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the office or agency of the Company maintained for that purpose in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts or, in the case of any Note that is a Global Security, in accordance with the procedures of The Depository Trust Company (“DTC”), or any successor depositary with respect to the Global Notes appointed under the Indenture, the “Depositary”), and its participants in effect from time to time; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register.
Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.
Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.
THE AMENDED AND RESTATED DECLARATION OF TRUST ESTABLISHING OFFICE PROPERTIES INCOME TRUST, DATED JUNE 8, 2009, AS AMENDED, AS FILED WITH THE STATE DEPARTMENT OF ASSESSMENTS AND TAXATION OF MARYLAND, PROVIDES THAT NO TRUSTEE, OFFICER, SHAREHOLDER, EMPLOYEE OR AGENT OF OFFICE PROPERTIES INCOME TRUST SHALL BE HELD TO ANY PERSONAL 
A-1

LIABILITY, JOINTLY OR SEVERALLY, FOR ANY OBLIGATION OF, OR CLAIM AGAINST, OFFICE PROPERTIES INCOME TRUST.  ALL PERSONS DEALING WITH OFFICE PROPERTIES INCOME TRUST IN ANY WAY SHALL LOOK ONLY TO THE ASSETS OF OFFICE PROPERTIES INCOME TRUST FOR THE PAYMENT OF ANY SUM OR THE PERFORMANCE OF ANY OBLIGATION.
IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.
												
	Dated:		OFFICE PROPERTIES INCOME TRUST
	
				
				
			By:______________________________________	
			Name:	
			Title:	
				
	CERTIFICATE OF AUTHENTICATION

	Dated:			
				
	This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture.
				
			 U.S. BANK NATIONAL ASSOCIATION, as Trustee
	
				
				
			By:______________________________________	
			Name:	
			Title:	

A-2

[Form of Reverse of Security]

1.    General.  This Security is one of a duly authorized issue of securities of the Company (the “Securities”),  issued and to be issued in one or more series under an Indenture, dated as of July 20, 2017 (the “Base Indenture”), between the Company and U.S. Bank National Association (the “Trustee”, which term includes any successor trustee under the Base Indenture), as supplemented by a Fourth Supplemental Indenture, dated as of August 13, 2021 (as amended, supplemented or otherwise modified from time to time, the “Supplemental Indenture” and the Base Indenture, as supplemented by such Supplemental Indenture, the “Indenture”), between the Company and the Trustee, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee, and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.  This Security is one of the series designated on the face hereof (such series, the “Notes”).
2.    Optional Redemption.  The Notes will be subject to redemption in whole at any time or in part from time to time prior to their maturity at the option of the Company upon not less than fifteen (15) nor more than sixty (60) days’ notice to each Holder of Notes to be redeemed at its address appearing in the Security Register, or, in the case of any Note that is a Global Security, in accordance with the procedures of the Depositary and its participants in effect from time to time, at a Redemption Price equal to the sum of (i) the principal amount of the Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including, the applicable Redemption Date and (ii) the Make-Whole Amount, if any (it being understood that if the Notes are redeemed on or after January 1, 2027, the Make-Whole Amount equals zero).  
As used herein, the term “Make-Whole Amount” means the excess, if any, of (i) the aggregate present value as of the date of redemption of each dollar of principal being redeemed and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable in respect of such dollar if such redemption had been made on January 1, 2027, determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (determined on the third Business Day preceding the date such notice of redemption is given) from the date on which such principal and interest would have been payable if such redemption had been made on January 1, 2027 over (ii) the aggregate principal amount of the notes being redeemed. In the case of any redemption of  the notes on or after January 1, 2027, the Make-Whole Amount will equal zero. The Make-Whole Amount shall be calculated by the Company and set forth in an Officer’s Certificate delivered to the Trustee, and the Trustee shall be entitled to rely on said Officer’s Certificate.
As used herein, the term “Reinvestment Rate” means a rate per annum equal to the sum of 0.250% (twenty five one hundredths of one percent), plus the yield on treasury securities at constant maturity under the heading “Week Ending” published in the Statistical Release under the caption “Treasury Constant Maturities” for the maturity (rounded to the nearest month) corresponding to the remaining life to maturity of the notes (which shall be deemed to be January 1, 2027) as of the payment date of the principal being redeemed. If no maturity exactly corresponds to such maturity, yields for the two published maturities most closely corresponding to such maturity shall be calculated pursuant to the immediately preceding sentence and the Reinvestment Rate shall be interpolated or extrapolated from such yields on a straight-line basis, rounding in each of such relevant periods to the nearest month. For purposes of calculating the Reinvestment Rate, the most recent Statistical Release published prior to the date of determination of the Make-Whole Amount shall be used.
As used herein, the term “Statistical Release” means the statistical release designated “H.15” or any successor publication which is published daily by the Federal Reserve System and which establishes yields on actively traded United States government securities adjusted to constant maturities or, if such statistical release (or any successor publication) is not published at the time of any determination under the Indenture, then any publicly available source of similar market data used for this purpose in accordance with customary market practice which shall be designated by the Company.
The Company shall not be required to make sinking fund or redemption payments with respect to the Notes.
In the event of redemption of this Security in part only, a new Note or Notes and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.
A-3

3.    Discharge and Defeasance.  The Indenture contains provisions for discharge or defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture.
4.    Defaults and Remedies.  If an Event of Default with respect to the Notes shall occur and be continuing, the principal of the Notes, plus accrued and unpaid interest thereon, may be declared due and payable in the manner and with the effect provided in the Indenture.
5.    Actions of Holders.  The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of not less than a majority in principal amount of the Securities at the time Outstanding of each series to be affected.  The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange therefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.
As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or this Security or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Notes, the Holders of not less than a majority in principal amount of the Notes at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity, and the Trustee shall not have received from the Holders of a majority in principal amount of Notes at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for sixty (60) days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein.
6.    Payments Not Impaired.  No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed.
7.    Denominations, Transfer, Exchange.  As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.
The Notes are issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Notes are exchangeable for a like aggregate principal amount of Notes and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.
No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.
8.    Persons Deemed Owners.  Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.
A-4

9.    Defined Terms.  All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture.

A-5

[ASSIGNMENT FORM]
ABBREVIATIONS
The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they were written out in full according to applicable laws or regulations:
																		
	TEN COM --	as tenants in common	UNIF GIFT MIN ACT --		Custodian	
	TEN ENT  --	as tenants by the entireties		(Cust)		(Minor)
	JT TEN      --	as joint tenants with right of survivorship	Under Uniform Gifts to Minors
		and not as tenants in common		Act		
					(State)	

Additional abbreviations may also be used though not in the above list.
______________________________________
FOR VALUE RECEIVED, the undersigned registered Holder hereby sell(s), assign(s) and transfer(s) unto
PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE 
			
	

															
					

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS OF ASSIGNEE
															
					

the within security and all rights thereunder, hereby irrevocably constituting and appointing
															
					

Attorney
to transfer said security on the books of the Company with full power of substitution in the premises.

Dated:                        Signed:                             
Notice:  The signature to this assignment must correspond with the name as it appears upon the face of the within security in every particular, without alteration or enlargement or any change whatever.
                        Signature Guarantee*:___________________
*  Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to the Trustee).
A-6

[Include this Schedule only for a Global Security]
SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL SECURITY
The initial principal amount of this Global Security is $[●].
The following exchanges, transfers or cancellations of this Global Security have been made:
 
																											
									
	Date of
Exchange
	  	Amount of
Decrease in
Principal
Amount of this
Global Security
	  	Amount of
Increase in
Principal
Amount of this
Global Security
	  	Principal
Amount of this
Global Security
Following Such
Decrease (or
Increase)
	  	Signature of
Authorized
Officer of
Trustee 

A-7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]